Compounds targeting KRAS g12d mutations and their uses
Small molecule molecular glue compounds enhance the interaction between KRAS G12D and CRBN, addressing the 'undruggable' nature of KRAS G12D mutations by facilitating its degradation, thereby offering an effective therapeutic approach for KRAS G12D-driven cancers.
Patent Information
- Application Number
- PCT/IB2024/054989
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-22
- Filing Date
- 2024-05-22
- Publication Date
- 2024-11-28
AI Technical Summary
Current KRAS-targeting therapeutics have limited success due to the 'undruggable' nature of KRAS G12D and G12V mutations, particularly because of permeability issues with large PROTAC molecules and sensitivity to genetic instability, as well as the 'Hook Effect' that occurs at high concentrations, which fails to induce proximity between KRAS and CRBN effectively.
Development of small molecule molecular glue (MG) compounds that enhance protein-protein interactions between KRAS mutants and E3 ligases, specifically designing MG molecules to stabilize the interaction between KRAS G12D and CRBN, facilitating the degradation of KRAS G12D through orthosteric and allosteric approaches using in silico methods and molecular dynamics simulations.
The MG compounds effectively target and degrade KRAS G12D, overcoming the limitations of existing therapeutics by stabilizing the complex and promoting ubiquitination, demonstrating significant anti-tumor efficacy in preclinical models, particularly in pancreatic cancer cells with KRAS G12D mutation.
Smart Images

Figure IB2024054989_28112024_PF_FP_ABST
Abstract
Description
COMPOUNDS TARGETING KRAS G12D MUTATIONS AND THEIR USESFIELD OF THE INVENTION
[0001] The present disclosure relates to compounds targeting KRAS G12D and G12V mutations and uses thereof.BACKGROUND OF THE INVENTION
[0002] KRAS (Kirsten rat sarcoma) is an important signaling protein (GTPase) involved in cell proliferation and differentiation - the GTP-bound KRAS is ‘active’, inducing proliferation signals via the MAPK pathway. Mutations in KRAS potentially lead to cancer by the overactivation of KRAS. Some common mutants of KRAS are KRAS G12C, G12D, G12V etc. The residue G12 is a critical residue in the GDP / GTP binding pocket and mutations of G12 potentially lead to resistance to GAP-catalyzed hydrolysis, causing KRAS to be chronically active. Mutations, therefore chronic activation, of KRAS is common in many cancers. KRAS mutation is found in -90% of pancreatic cancer, -40% of colorectal cancer (CRC) and -19 of non-small cell lung cancer (NSCLC). Out of the three most common mutants (G12C, G12D, and G12V), G12D is found in the greatest proportion (over one thirds). This mutant is prevalent in especially colorectal cancer, where KRAS G12D mutant appears approximately 16% out of all cases. In NSCLC, the G12D mutant appears approximately at 4%, which clearly is not negligible.
[0003] Currently, there are two major mechanisms in which KRAS has been targeted: by blocking the interaction between KRAS -Effector, or by trapping KRAS in its inactive state. KRAS-targeted therapeutics showed limited success in only G12C mutants due to the cysteine’s ability to form covalent bonds with exogenous ligands. Other mutants (including the wild-type) are known to be ‘undruggable’ due to the lack of orthosteric and allosteric binding sites. Various investigational new drugs targeting KRAS G12C have entered clinical trials: Lumakras (AMG510) developed by Amgen, MRTX849 and MRTX1133 both developed by Mirati Therapeutics.
[0004] Based on the KRAS G12C inhibitors developed, PROTACs (Proteolysis Targeting Chimeras), a heterobifunctional molecule that comprises of the KRAS ligand and a ligand for an E3 ubiquitin ligase linked by a suitable linker, has been developed. A prominent example of such PROTAC would be LC2, an experimental PROTAC molecule that recruits CRBN (Cereblon), reported to result in poly-ubiquitination of KRAS, thus proteosome-mediated degradation of the protein. PROTACS are sought after as a novel paradigm in therapeutics, butit does come with several critical limitations. PROTACs are inherently large molecules (of -1000 Da), which can lead to permeability issues. Also, PROTACs are sensitive to additional KRAS mutations caused by the genetic instability of the tumor cell, as ligands designed to specifically bind to KRAS G12C is very sensitive to the conformation of the binding pocket. On top of this, the ‘Hook Effect’ is the most maj or issue presented by PROTACs, where at high concentrations of PROTAC, it essentially acts as a monovalent ligand, binding to both KRAS and CRBN individually, failing to induce proximity between them.BRIEF SUMMARY OF THE INVENTION
[0005] Disclosed herein are compounds of any one of the following structures, enantiomers or diastereomers thereof, or pharmaceutical acceptable salts thereof:3, and
[0006] Disclosed herein are compounds of the following structure, an enantiomer or diastereomer thereof, or its pharmaceutical acceptable salt:wherein R is H or Cl to C4 alkyl, and each R’ is independently Cl - C2 alkyl. In some embodiments, the compound is, or a pharmaceutical acceptable salt thereof
[0007] Also disclosed herein are compounds of the following structure, an enantiomer or diastereomer thereof, or its pharmaceutical acceptable salt:wherein each R is independently Cl to C4 alkyl, and R’ is Cl - C4 alkyl substituted at any position by a phenyl group. In some embodiments, the compound is, or a pharmaceutical acceptable salt thereof.
[0008] Disclosed herein are compounds of the following structure, an enantiomer or diastereomer thereof, or its pharmaceutical acceptable salt:wherein R” is Cl to C4 alkyl substituted at any position with one of the following:
[0009] In some embodiments, the compound is, or a pharmaceutical acceptable salt thereof.
[0010] Disclosed herein are pharmaceutical compositions comprising at least one of the compounds disclosed herein or an enantiomer or diastereomer thereof, or its pharmaceutical acceptable salt, and a pharmaceutically acceptable excipient.
[0011] Disclosed herein are methods of inhibiting a KRAS G12D and / or G12V mutation in a cell, comprising contacting the cell with at least one of the compounds or pharmaceutical compositions disclosed herein.
[0012] Disclosed herein are methods of treating cancer in a subject in need of treatment, comprising administering to the subject a therapeutically effective amount of at least one of the compounds or the pharmaceutical compositions disclosed herein. In some embodiments, thecancer is lung cancer, pancreatic cancer, or colorectal cancer. In some embodiments, the method of treating cancer comprises administering a therapeutic effective amount of an additional pharmaceutically active compound to the subject.
[0013] In some embodiments, the cancer can be, but not limited to, lung cancer, pancreatic cancer, or colorectal cancer. Pharmaceutical compositions comprising a compound disclosed herein, together with a pharmaceutically acceptable excipient, such as a diluent or carrier, are also provided herein. Suitable compounds and pharmaceutical compositions for use include those in which the compound can be administered in an effective amount to accomplish its intended purpose.BRIEF DESCRIPTION OF THE FIGURES
[0014] FIGS. 1A and IB show the structures of the MG candidate compounds of the disclosure herein. Compounds 1 and 10-12 are synthesizeable structures and compound 7 is a synthesized structure.
[0015] FIG. 2A is a schematic diagram of the production process of candidate compound 1 of FIG. 1A. FIG. 2B is a schematic diagram of the production process of candidate compound 7 in FIG. 1A. FIG. 2C is a schematic diagram of the production process of candidate compound 10 of FIG. IB. FIG. 2D is a schematic diagram of the production process of candidate compound 11 of FIG. IB. FIG. 2E is a schematic diagram of the production process of candidate compound 12 in FIG. IB.
[0016] FIG. 3 shows the simulated metastable complexes of KRAS G12D and CRBN (left); and KRAS G12C and CRBN (right).
[0017] FIG. 4 shows preliminary results of KRAS G12D and G12C molecular glue molecules discovered using the strategy of the present disclosure, and the dotted green lines on the bottom diagram represent ligand protein interactions.
[0018] FIG. 5 is a picture of a sample MG molecule inserted in the interspace between KRAS and CRBN, where the C-terminal of KRAS is located opposite the binding interspace, enabling successful degradation.
[0019] FIG. 6 is an image showing the MD result for the MG02 molecule, and this simulation was accelerated by raising the temperature higher than the physiological temperature. Note that the protein complex dissociates slowly without the MG ligand.
[0020] FIG. 7 shows the RMSD (Root-Mean-Square-Deviation) peak (left) for the KRAS G12CMD simulation and the RMSD peak (right) for the KRAS G12DMD simulation. It had a relatively high RMSD peak in the absence of MG ligands for both G12C and G12D, and theRMSD peak was relatively low in MG ligands. This indicated that the stabilization of the complex was improved. Simulation is yet to be performed on MG05.
[0021] FIGS. 8A-8C show ternary complex formation assay of CRBN-KRAS mutant-MG. These figures show the kinetic analysis of the sensorgram and the estimation of various kinetic parameters using the 1:1 Langmuir binding model. The distinct peaks observed at different concentrations provide insights into the binding behavior, while the estimated kinetic parameters offer quantitative information regarding the binding kinetics and affinity of the interaction. SPR Kinetics analysis was obtained by using a different concentration of 06061-1. SPR sensorgram. Kinetics analysis kon ((1 / M*s)) : 1.71e4, koff (1 / s) : 5.54e-3, KD (M) : 3.25e-7, tl / 2 : 1.25el KD : 325 nM. FIG. 8A Ternary complex formation assay of CRBN- KRAS G12D-MG; FIG. 8B Ternary complex formation assay of CRBN-KRAS WT-MG. FIG. 8C shows that IPS-06061 binds specifically to KRAS G12D, forming a ternary complex between CRBN-KRASG12D-IPS06061 : High selective for KRAS G12D; and IPS-06061 specifically binds to and degrades KRAS G12D mutant without affecting KRAS Wild Type.
[0022] FIG. 9 shows Solid Phase Cell-Free Assay System using A Novel PPIExplorer-based Ubiquitination of KRAS G12D using CRBN, an E3 ligase. IPS-06061 promoted the ubiquitination of KRAS G12D in a dose-dependent manner via IPSChip-based solid-phase cell-free ubiquitination assay.
[0023] FIG. 10. KRAS G12D degradation by IPS-KRAS MGD. IPS-06061 exhibits Timedependent degradation of KRAS G12D; IPS-06061 exhibited DC50 <500 nM and Dmax >90% for G12D; and no effect on the degradation of KRAS WT in Caco-2 cells.
[0024] FIG. 11. Strong Anti-Tumor efficacy of IPS-KRAS MGD in vivo. Oral efficacy in Xenograft mice bearing AsPC-1 pancreatic cancer cells with KRAS G12D. IPS-06061 dosed at 80 mpk BiW demonstrated -100% TGI; Maximum degradation of >75% achieved at 28 days after treatment; No body weight effect.DETAILED DESCRIPTION OF THE INVENTION
[0025] Disclosed herein are novel compounds targeting KRAS G12D and G12V mutation and uses for the compounds targeting KRAS G12D and G12V mutation.
[0026] Disclosured herein is a compound of any one of Formulas 1 to 13 below, or a stereoisomer, a prodrug, a tautomer, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer, or a pharmaceutically acceptable salt of a tautomer:Chemical formula 1-1313
[0027] Disclosed herein are pharmaceutical compositions comprising at least one of the compounds of disclosed herein and a pharmaceutically acceptable excipient. Also disclosed herein are methods of inhibiting KRAS G12D mutations in a cell, comprising contacting the cell with a compound disclosed herein or a composition disclosed herein.
[0028] Disclosed herein are methods of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of a compound disclosed herein or a composition disclosed herein.
[0029] In some embodiments, the cancer can be, but not limited to, lung cancer, pancreatic cancer, or colorectal cancer. Pharmaceutical compositions comprising the compounds disclosed herein, together with pharmaceutically acceptable excipients, such as diluents or carriers, are also provided herein. Suitable compounds and pharmaceutical compositions for use in the present disclosure include those in which the compound can be administered in an effective amount to accomplish its intended purpose. Administration of the compounds is described in more detail below.
[0030] Suitable pharmaceutical formulations can be determined by the route of administration and the desired dosage (Remington's Pharmaceutical Sciences, 1435-712 (18th ed., Mack Publishing Co, Easton, Pennsylvania, 1990)). Formulation can affect the physical state, stability, rate of in vivo release, and in vivo elimination of the administered agent. Depending on the route of administration, the appropriate dose can be calculated based on body weight, body surface area, or organ size. Further refinements of the calculations necessary to determine an appropriate therapeutic dose are routinely made without undue experimentation, particularly in light of the analytical and dosage information disclosed herein, as well as pharmacokinetic data that can be obtained from animal or human clinical trials.
[0031] " Pharmaceutical acceptable" or "pharmaceutically acceptable" refers to molecular entities and compositions that do not produce adverse reactions, allergic reactions, or other adverse effects when administered to animals or humans. As used herein, the term "pharmaceutically acceptable" includes all solvents, dispersing media, coatings, antibacterial and antifungal agents, isotonic agents, and absorbent carriers. The use of such excipients for pharmaceutically active substances is well known in this field. Their use in therapeutic compositions is contemplated, except where any conventional medium or agent is incompatible with the therapeutic composition. Supplemental active ingredients can also be included in the composition. In some embodiments, the formulation comprises corn syrup solids, high oleic safflower oil, coconut oil, soybean oil, L-leucine, calcium trisphosphate, E-tyrosine, L-proline, L-lysine acetate, DATEM (emulsifier), L-glutamine, L-valine, dipotassium phosphate, L- isopropylpotassium phosphateE-isoleucine, E-arginine, L-alanine, glycine, L-asparagine monohydrate, L-serine, potassium citrate, L-threonine, sodium citrate, magnesium chloride, L- histidine, L-methionine, ascorbic acid, calcium carbonate, L-glutamic acid, L-cystine diphosphate, L-tryptophan, L-aspartic acid, choline chloride, taurine, m-inositol, ferroussulfate, ascorbyl palmitate, zinc sulfate, L-camitine, alpha-tocopheryl acetate, sodium chloride, niacinamide, mixed tocopherols, calcium pantothenate, cupric sulfate, thiamine chloride, vitamin A palmitate, manganese sulfate, riboflavin, pyridoxine hydrochloride, folic acid, betacarotene, potassium iodide, phylloquinone, biotin, sodium selenate, chromium chloride, sodium molybdate, vitamin D3, and cyanocobalamin.
[0032] The compounds can also be present as pharmaceutically acceptable salts in pharmaceutical compositions. As used herein, the term "pharmaceutically acceptable salt" includes, for example, base adducts and acid adducts.
[0033] A pharmaceutically acceptable base adduct salt can be formed from a metal or an amine, for example, an alkali and alkaline earth metal or an organic amine. The pharmaceutically acceptable salt of the compound can also be prepared using a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those skilled in this field and include alkali, alkaline earth, ammonium, and quaternary ammonium cations. Carbonates or hydrogen carbonate salts are also possible. Examples of metals used as cations include sodium, potassium, magnesium, ammonium, calcium, or ferric iron. Examples of suitable amines include isopropylamine, trimethylamine, histidine, N,N'- dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine.
[0034] Pharmaceutically acceptable acid adducts include inorganic or organic acid salts. Examples of suitable acid salts include hydrochloride, formate, acetate, citrate, salicylate, nitrate, and phosphate. Other suitable pharmaceutically acceptable salts are well known to those skilled in this field and include, for example, formic acid, acetic acid, citric acid, oxalic acid, tartaric acid or mandelic acid, hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; Organic carboxylic acids, sulfonic acids, sulfuric or phosphoric acids, or N- substituted sulfamic acids, such as acetic acid, trifluoroacetic acid (TFA), propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2- phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, nicotinic acid, or isonicotinic acid; and 20 alpha-amino acids that are involved in the synthesis of proteins in nature amino acids such as the 20 alpha amino acids including glutamic acid or aspartic acid, and also phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2 -hydroxy ethanesulfonic acid, ethane 1,2- disulfonic acid, benzenesulfonic acid, and 4-methylbenzenesulfonic acid, naphthalene 2- sulfonic acid, naphthalene 1,5-disulfonic acid, 2- or 3 -phosphoglycerate, glucose 6-phosphate,N-cyclohexylsulfamic acid (formation of cyclamate), or other acid organic compounds such as ascorbic acid.
[0035] Pharmaceutical compositions comprising the compounds disclosed herein can be prepared in conventional ways, for example, by conventional mixing, dissolving, granulating, sugar-coating, powdering, emulsifying, encapsulating, or lyophilizing processes. The appropriate formulation depends on the route of administration selected.
[0036] For oral administration, suitable compositions can be readily formulated by combining the compounds disclosed herein with pharmaceutically acceptable excipients, such as carriers well known in this fireld. Such excipients and carriers allow the compounds to be formulated as tablets, pills, disintegrating tablets, capsules, liquids, gels, syrups, slurries, suspensions, and the like for oral ingestion by the patient being treated. Oral pharmaceutical preparations can be obtained by adding the compounds disclosed herein together with solid excipients, optionally grinding the resulting mixture, adding suitable auxiliaries if desired, and processing the mixture into a granular mixture to obtain a tablet or dragee core. Suitable excipients include, for example, fillers and cellulose preparations. If desired, disintegrating agents can be added. Pharmaceutically acceptable ingredients are well known in various types of formulations and can be, for example, binders (e.g., natural or synthetic polymers), glossing agents, surfactants, sweeteners and flavoring agents, coating materials, preservatives, dyes, thickeners, auxiliaries, antimicrobial agents, antioxidants, and carriers (for various types of formulations).
[0037] When a therapeutically effective amount of a compound disclosed herein is administered orally, the composition is typically in the form of a solid (e.g., tablet, capsule, disintegrant, acid, or trochet) or liquid formulation (e.g., aqueous suspension, solution, elixir, or syrup). When administered in tablet form, the composition can further comprise a functional solid and / or a solid carrier such as gelatin or an augmentant. The tablets, capsules, and antacids can contain from about 1 to about 95% of the compound, or from about 15 to about 90% of the compound.
[0038] When administered in liquid or suspension form, a functional liquid and / or liquid carrier, such as water, petroleum, or oil of animal or plant origin, can be added. The liquid form of the composition can further comprise physiologic saline, a sugar alcohol solution, a dextrose or other sugar solution, or a glycol. When administered in liquid or suspension form, the composition can contain from about 0.5 to about 90% by weight of the disclosed herein, or from about 1 to about 50% by weight of the compound disclosed herein. In some embodiments, the liquid body carrier is non-aqueous or substantially non-aqueous. In administration in liquidform, the composition is can be supplied as a rapidly dissolving solid formulation for suspension or dissolution immediately prior to administration.
[0039] When a therapeutically effective amount of a compound disclosed herein is administered by intravenous, dermal, or subcutaneous injection, the composition is in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable solutions, with particular regard to pH, isotonicity, stability, and the like, is within this field.
[0040] In some embodiments, the compositions for intravenous, dermal, or subcutaneous injection typically contain, in addition to the compounds disclosed herein, an isotonic vehicle.
[0041] Such compositions can be formulated for administration as a solution of a free base or pharmaceutically acceptable salt in water suitably mixed with a surfactant such as hydroxypropyl cellulose. The dispersion can also be prepared in glycerol, liquid polyethylene glycol, and mixtures thereof, and in oils. Under normal conditions of storage and use, these preparations can optionally contain a preservative to prevent the growth of microorganisms.
[0042] Injectable compositions can include sterile aqueous solutions, suspensions or dispersions for the ready preparation of sterile injectable solutions, suspensions or dispersions, and sterilizing powders. In some embodiments, the form should be sterile and fluid to the extent that easy syringeability exists. It shall be stable under the conditions of manufacture and storage, and shall be resistant to the contaminating action of microorganisms such as bacteria and fungi by the optional inclusion of a preservative.
[0043] The carrier can be, for example, a solvent or dispersion medium comprising water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils. In some embodiments, the carrier is non-aqueous or substantially non-aqueous.
[0044] Suitable fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size of the compound in the dispersion embodiments, and by the use of surfactants. The prevention of microbial action can be caused by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenols, sorbic acid, thimerosal, etc.
[0045] In some embodiments, it can be desirable to include an isotonicizing agent, e.g., sugar or sodium chloride. Delayed absorption of the injectable composition can be caused by the use of agents in the composition that delay absorption, for example, aluminum monostearate and gelatin.
[0046] Sterile injectable solutions are prepared by including the active compound in a suitable solvent in the required amount, together with various other components listed above as needed, followed by sterile filtration. Generally, the dispersion is prepared by including various sterilized active.
[0047] Generally, the dispersion comprises a basic dispersion medium and various sterilized active ingredients in a sterilizing vehicle containing the other ingredients required from those listed above. In the embodiments of sterilizing powders for the preparation of sterile injectable solutions, some exemplary methods of preparation are vacuum-drying and freeze-drying techniques in which a powder of the active ingredient plus any additional desired ingredients is produced from a pre- sterilized and filtered solution thereof.
[0048] Delayed release or sustained release formulations can be formulated to achieve controlled release of the active compound in contact with body fluids in the GI tract, and to provide substantially constant and effective levels of the active compound in plasma. For example, release can be controlled by one or more of dissolution, diffusion, and ion-exchange. In addition, delayed release fold approaches can enhance absorption via a saturated or restricted pathway within the GI tract. For example, compounds can be embedded in a polymeric matrix of a biodegradable polymer, a water-soluble polymer, or a mixture of the two for this purpose, and optionally a suitable surfactant.
[0049] Embedding can mean, in this context, the inclusion of micro-particles in the polymeric matrix. Controlled release formulations are also obtained through the encapsulation of dispersed microparticles or emulsified micro-droplets by known dispersion or emulsion coating techniques.
[0050] For administration by inhalation, the compounds disclosed herein are conveniently delivered in the form of an aerosol spray presentation from a pressurized pack or nebulizer, by the use of a suitable nebulizer. In the pressurized aerosol presentation, the unit of dosage can be determined by providing a valve for delivering a metered amount. Capsules and cartridges, e.g., of gelatin, for use in an inhaler or nebulizer can be formulated containing the compound and a suitable powdered base, e.g., a powdered mixture of lactose or starch, compound and a suitable powder base, for example a powdered mixture of lactose or starch.
[0051] The compounds disclosed herein can be formulated for parenteral administration by injection (e.g., by bolus injection or continuous infusion). Injectable formulations can be presented in unit dose form (e.g., in ampoules or multi-dose containers), with added preservatives. The composition can take the form of a suspension, solution, or emulsion in anoil or aqueous vehicle, and can contain a formulating agent such as a suspending agent, stabilizing agent, and / or dispersing agent.
[0052] Pharmaceutical formulations for parenteral administration comprise an aqueous solution of the compound in an aqueous form. Additionally, the suspension of the compound can be prepared as a suitable oily injection suspension.
[0053] Suitable lipophilic solvents or vehicles include fatty acid oils or synthetic fatty acid esters. The aqueous injection suspension can comprise a substance that increases the viscosity of the suspension. Optionally, the suspension can also include a suitable stabilizer or agent that increases the solubility of the compound and allows for the preparation of very concentrated solutions. Alternatively, the compositions can be in powder form for composition with a suitable vehicle (e.g., sterile non- pyrogenic water) prior to use.
[0054] The compounds disclosed herein can also be formulated as rectal compositions, e.g., suppositories or stasis enemas (e.g., including conventional suppository bases). In addition to the formulations described above, the compounds can also be formulated as depot preparations. Such prolonged- acting formulations can be administered by implantation (e.g., subcutaneous or intramuscular) or by intramuscular injection. Thus, for example, the present compounds can be formulated in a suitable polymer or hydrophobic material (e.g., as an emulsion in an acceptable oil) or ion exchange resin, or as a water-soluble derivative, e.g., as a water-soluble salt.
[0055] In particular, the compounds disclosed herein can be administered orally, buccally, or sublingually, in the form of tablets containing excipients such as starch or lactose, or as capsules or vaginal suppositories alone or mixed with excipients, or as elixirs or suspensions containing flavoring agents or colorants. These liquid preparations can be prepared with pharmaceutically acceptable excipients, such as suspending agents. The compounds can also be administered parenterally, e.g., intravenously, intramuscularly, subcutaneously, or intracoronary. For parenteral administration, the compounds are best used in the form of sterile aqueous solutions, which can contain other substances, e.g., salts, or sugar alcohols, e.g., mannitol, or glucose, to make the solution isotonic with blood.
[0056] For veterinary use, the compounds disclosed herein are administered in acceptable formulations as appropriate in accordance with normal veterinary practice. A veterinarian can readily determine the most appropriate dosing regimen and route of administration for a particular animal.
[0057] In some embodiments, all necessary components for the treatment of a KRAS-related disorder, using the compounds disclosed herein alone or in combination with other agents orinterventions traditionally used in the treatment of KRAS -related disorders, can be packaged as a kit.
[0058] Dislcosed herein are kits for use in the therapeutic intervention of a disease, comprising a compound disclosed herein, as well as a buffer and other ingredients for preparing a deliverable form of the medicament, and / or an instrument for delivering the medicament, and / or any agent used in combination therapy with the compounds disclosed herein, and / or a packaged set of medicament, including instructions for the treatment of the disease being packaged with the medicament.
[0059] The instructions can be fixed to any tangible medium, for example, printed paper, a computer-readable magnetic, or optical medium or can be instructions that reference a remote computer data source, such as a World Wide Web page accessible via the Internet.
[0060] "Therapeutically effective amount" means an amount that is effective to relieve an existing condition, prevent the development of a condition, or cure a condition in a subject being treated. Determination of an effective amount is within the capabilities of those skilled in this field, particularly in light of the detailed disclosure provided herein. In general, a "therapeutically effective amount" refers to an amount of a compound that results in the achievement of a desired effect. For example, a therapeutically effective amount of a compound disclosed herein reduces KRAS activity by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90%, compared to a control.
[0061] The amount of the compounds administered can depend on the subject being treated, the subject's age, health, sex, and weight, the type of concomitant treatment (if any), the severity of the pain, the nature of the desired effect, the mode and frequency of treatment, and the judgment of the prescribing physician. The frequency of dosing can also depend on pharmacodynamic effects on arterial oxygen pressure. However, without undue experimentation, the dosage, as understood and determinable by those skilled in this field, can be tailored to the individual subject, individual subject. This typically includes adjustments to the standard dose (e.g., a decrease in dose if the patient is underweight).
[0062] The mode and frequency of treatment, and the judgment of the prescribing physician. The frequency of dosing can also have a pharmacodynamic effect on arterial pharmacodynamic effects on arterial oxygen pressure. However, without undue experimentation, as understood and determined by those skilled in this field.
[0063] However, as understood and determinable by those skilled in the art, without undue experimentation, the most desirable dosage can be tailored to the individual subject. This typically involves adjustment of the standard dose (e.g., a decrease in dose if the patient is underweight).
[0064] While individual needs vary, determination of the optimal range of effective amounts of a compound is a matter of skill in the field. When administered to the liver, for example, a typical dose of a compound disclosed herein is about 0.05mg / kg / day to about 50 mg / kg / day, for example at least 0.05 mg / kg, at least 0.08 mg / kg. at least 0.1 mg / kg, at least 0.2 mg / kg, at least 0.3 mg / kg, at least 0.4 mg / kg, or at least 0.5 mg / kg, or less than 50 mg / kg, less than 40 mg / kg, less than 30 mg / kg can be less than or equal to 20 mg / kg, or less than or equal to 10 mg / kg, for example, about 2.5 mg / kg or less. It can be from (0.5 mg / kg x 5 kg) to about 5000 mg / day (50 mg / kg x 100 kg). For example, the dosage of the compound is about 0.1 mg / kg / day to about 50 mg / kg / day, about 0.05 mg / kg / day to about 10 mg / kg / day, about 0.05 mg / kg / day to about 5 mg / kg / day, about 0.05 mg / kg / day to about 3 mg / kg / day, about 0.07 mg / kg / day to about 3 mg / kg / day, about 0.09 mg / kg / day to about 3 mg / kg / day, about 0.05 mg / kg / day to about 0.1 mg / kg / day, about 0.1 mg / kg / day to about 0.1 mg / kg / day, 1 mg / kg / day, about 1 mg / kg / day to about 10 mg / kg / day, about 1 mg / kg / day to about 5 mg / kg / day to about 5 mg / kg / day, about 1 mg / kg / day to about 3 mg / day to about 3 mg / day to about 500 mg / day, about 5 mg / day to about 250 mg / day, about 10 mg / day to about 100 mg / day, about 3 mg / day to about 10 mg / day, or about 100 mg / day to about 250 mg / day. Such a dose can be administered in a single dose or can be divided into multiple doses.
[0065] Disclosed herein are methods of using the compounds or pharmaceutical compositions disclosed herein to treat disease conditions, including, but not limited to, diseases involving G12D and G12V KRAS mutations (e.g., cancer).
[0066] In some embodiments, methods of treating cancer are provided, which include administering an effective amount of any of the above-described pharmaceutical compositions including the compounds disclosed to a subject requiring it. In some embodiments, cancer is mediated by KRAS G12D and / or G12V mutations. In some embodiments, cancer is pancreatic cancer, colorectal cancer, or lung cancer. In some embodiments, cancer is gallbladder cancer, thyroid cancer, and bile duct cancer. In some embodiments, disclosed herein are methods of treating a disorder in a subject requiring disorder treatment, wherein the methods include determining whether the subject has KRAS G12D and / or G12V mutations and administering a therapeutic effective amount of at least one compound disclosed or a pharmaceuticallyacceptable salt thereof to the subject when it is determined that the subject has KRAS G12D and / or G12V mutations.
[0067] The disclosed compounds have the potential to inhibit immobilization-independent cell growth and thus tumor metastasis.
[0068] Disclosed herein are methods of treating hyperproliferative disorders in mammals, comprising administering a therapeutic effective amount of a compound, or a pharmaceutically acceptable salt thereof, to mammals. In some embodiments, the method includes cancer, such as acute myeloid leukemia, cancer in adolescents, child adrenocortical carcinoma, AIDS- related cancer (e.g., lymphoma and Kaposi's Sarcoma), anus cancer, appendix cancer, astrocytoma, atypical malformations, underlying cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain stem glioma, brain tumor, breast cancer, bronchial cancer, Burkitt lymphoma, carcinoma, atypical carcinoma, embryo, Sex tumors, germ cell tumors, primary lymphoma, cervical cancer, childhood cancer, ectomyeloma, heart tumor, chronic lymphocyte leukemia (CLL), chronic myeloproliferative disorders, colon cancer, colorectal cancer, cranial pharynx, skin T-cell lymphoma, extracorporeal carcinoma in situ (DCIS), embryonic tumors, CNS cancer, endometrial cancer, upper cell carcinoma, esophageal cancer, sensory neuroblastoma, ewing sarcoma, eutectomy sarcoma, extracranial germ cell tumors, eye cancer, fibroblast of bone, gallbladder cancer, stomach cancer, gastrointestinal carcinoma, gastrointestinal stromal tumors (GIST), germ cell tumors, gestational villous tumors, hairy cell leukemia, head and neck cancer, heart cancer, liver cancer, Hodgkin lymphoma, low-head cancer, guided melanoma, docell tumor, pancreatic neuroendocrine tumor, kidney cancer, laryngeal cancer, lip and oral cancer, liver cancer, distal lobular carcinoma (lobular carcinoma in situ, LCIS), metastatic squamous cell neck cancer with lung cancer, multiple endocrine adenocarcinoma, multiple myeloma / type cell tumors, myeloma, bone marrow dysplasia / myeloproliferative tumors, multiple myeloma, multiple myeloma / myeloproliferative tumors, Merkel cell carcinoma, malignant mesothelioma, nasal and sinus cancer, neuroblastoma, non-Hodgkin lymphoma, non-small cell lung cancer, non-small cell lung cancer (NSCLC), oral cancer, lip and oral cancer, oral cancer, oral cancer, oral cancer, myeloid dysplasia syndrome, multiple myeloma, Merkel cell carcinoma, malignancy and osteomyeloma, malignant mesothelioma, malignancy and osteosarcoma of bone, nasal and sinus cancer, neuroblastoma, non-Hodgkin's lymphoma, non-small cell lung cancer, oral cancer, oral cancer, lip and oral pharyngeal cancerCancer,
[0069] Ovarian cancer, pancreatic cancer, papillomatosis, adrenal ganglionoma, sinus and nasal cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pleural lung blastoma,primary central nervous system (CNS) lymphoma, prostate cancer, rectal cancer, transitional cell cancer, retinal stem cell carcinoma, rhabdomyosarcoma, salivary adenocarcinoma, skin cancer, gastric cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, T-cell lymphoma, testicular cancer, throat cancer, thymoma and thymus carcinoma, transitional cell cancer of thyroid cancer, pyelo and ureter, nutritional membrane tumor, rare cancer in childhood, urethral cancer, uterine sarcoma, vaginal cancer, vulva cancer, or virus-induced cancer. In some embodiments, the method relates to the treatment of subjects suffering from non-cancerous hyperproliferative disorder, non-cancerous hyperproliferative disorder, and virus-induced cancer. For example, it is about the treatment of benign hyperplasia of the skin (e.g., psoriasis), relapse stenosis, or benign prostatic hyperplasia (e.g., BPH).
[0070] In some embodiments, the treatment methods relate to the treatment of lung cancer, which includes administering an effective amount of any of the above-described compounds (or pharmaceutical compositions including the same) to a subject requiring the same. In some embodiments, lung cancer is a non-small cell lung carcinoma (NSCLC), such as adenocarcinoma, flat-cell lung carcinoma, or large-cell lung carcinoma. In some embodiments, lung cancer is a small cell lung carcinoma. Other lung cancers treatable with the disclosed compounds include, but are not limited to, adenocarcinoma, carcinoma, and undifferentiated carcinoma.
[0071] Disclosed herein are methods of regulating this protein activity by contacting KRAS G12D and G12V mutant proteins with effective amounts of the compounds disclosed herein.
[0072] This regulation can be inhibiting or activating the protein activity. In some embodiments, disclosed herein are methods of inhibiting protein activity by contacting t KRAS G12D and G12V mutan proteins with an effective amount of the compounds disclosed herein. In some embodiments, provided herein are methods of inhibiting G12D and G12V mutant KRAS protein activity by contacting cells, tissues, or organs expressing a protein of interest.
[0073] In some embodiments, provided herein are methods of inhibiting protein activity in a subject by administering an effective amount of the compounds disclosed herein to a subject including, but not limited to, rodents and mammals (e.g., humans). In some embodiments, the control percentage exceeds 25%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%. In some embodiments, the inhibition percentage exceeds 25%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%.
[0074] Provided herein are methods for combination therapy in which an agent or even a set of overlapping target enzymes known to control another pathway, or other components of thepathway, is combined with one or more of the compounds disclosed herein, or a pharmaceutically acceptable salt thereof.
[0075] In one aspect, such therapy includes, but is not limited to, a combination of one or more compounds disclosed herein and chemotherapy, therapeutic antibodies, and radiation therapy to provide synergistic or commercial therapeutic effects.
[0076] Many chemotherapy agents are currently known in the field and can be used in combination with the compounds disclosed herein. In some embodiments, chemotherapy agents are selected from the group consisting of mitotic inhibitors, alkylators, antithrombotic substances, insertion antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, local isomerase inhibitors, biological response regulators, anti-hormones, angiogenesis inhibitors, and anti-androgenics. Non-limiting examples include, but are not limited to, chemotherapy agents, cytotoxic agents, and non-peptide small molecules such as Gleevec®) (imatinib mesylate), kiprolis®) (carpylzomib), Velcade®, casodekode (borzomib)
[0077] It is a host of chemotherapy drugs, as well as Casodex (bicalutamide), Iressa®, and adriamycin. Non-limiting examples of chemotherapy drugs include alkylating agents such as thiotepa and cyclophosphamide (CYTOXANTM); alkyl sulfonates such as subplates, improsulfan and piposulfan; aziridine, such as benzodopa, carbokuon, meturredopa, and uredopa; ethylene imine and methylmelamine comprising altretamine, triethylenemelamine, triethylenephosphoramide, triethylene thiophosphoramide, and trimethylolomelamine; nitrogen mustard; e.g. chlorambushil, chlomaphazin, chlorophosphamide, estra mustin, ifphosphamide, mecloretamine, melethamine, noembikin, phenesterin, prednimustin, trophosphamide, uracil mustard; nitrosorbic acid urea, e.g., carmustin, chlorozotosin, potemustin, romustin, nimustin, lanimustin; antibiotics, e.g., aclacinomycin, actinomycin, anthramycin, azerin, bleomycin, cactinomycin, carabicin, caraminophilin, casodexTM, chromomycin, dactinomycin, downorubicin,
[0078] Dettorubicin, 6-diazo-5-oxo-L- norleucine, doxorubicin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycin, mycophenolic acid, nogalamycin, olivomycin, peplomycin, potpyrromycin, puromycin, kuelamycin, rhodorubicin, streptonigreens, streptozocin, tuberculosis, uvenimex, ginostatin, zorubicin; antimetics, e.g., methotrexate and 5 -fluorouracil (5-FU); Folic acid analogs, for example, denopterin, methotrexate, pteropterin, trimetrexate; purine analogs, for example, fludarabin, 6-mercaptopurin, thiamiprine, thioguanin; pyrimidine analogs, for example, ancytabin, azacitidine, 6-azauridine, Carmopur, citarabin, dideoxyuridine, doxifluridine, enositabin, floxiridine, androgen, for example, calusterone, dromostanolone propionate, epithiostanol, meftiostan, testolactone; anti-businagents, such as aminoglutamide, mitotan, and trilostan; folic acid supplements, such as polyline acid; acetone; aldophosphamide glycoside; aminolevulin; amsaacrine; vestravusilene; edatraxate; defoamine; demecolcine; diazikuon; elformithin; eliptinium acetate; ethoglucid; ethoglucid; nitrate; hydroxyurea; lentinan; ronidamine; mitoguazone; mitoguazone; mittoxanthron; mopyrin; fenamol; pentostatin; pyraubic acid; 2-ethylhydrazide; procarbazine; spiroguic acid; tenuazonic acid; triazicuonic acid; 2,2"'-trichlorotriethylamine; urethane; bindecine; dacarb azine; Mannomustin; mitobronitol; mitoractol; pipobroman; thacitosin; arabinoside ("Ara-C"); cyclophosphamide; thiotepha; thioxane, e.g., paclitaxel and docetaxel; retinoic acid; esperamicin; capecitavin; and any of the above pharmaceutically acceptable salts, acids, or derivatives.
[0079] As suitable chemotherapy cell conditioners, anti-estrogen agents including tamoxifen, (NolvadexTM), raloxifen, cyclization inhibition 4(5)-imidazole, 4-hydroxytamoxifen, trioxyfen, kheoxyfen, LY 117018, onapristone, and toremyfen; and anti-androgen agents, such as plutamide, nilutamide, bicalutamide, leuprolide, and gocerelin; chlorambucyl; gemcitabin; 6-thioguanine; mercaptopurin; platinum analogs, e.g., cisplatin and carboplatin; vincoplatin; platinum; etoposide (VP- 16); ifosfamide; mitomycin C; mitoxanthron; vincristine; vinorelvin; nabelvin; teneposide; dowonomycin; aminopterin; zeloda; ibandronate; local isomerase inhibitor RFS 2000; difluoromethylornithine (DMFO) acts to regulate or inhibit hormone action on tumors. Anti-hormone drugs are also included.
[0080] If desired, the compound or pharmaceutical composition disclosed herein can be used in combination with a commonly prescribed anticancer drugs, such as Herceptin®), Avastin®, Erbitux®, Rituxan®, Taxol®, Arimidex®, Arimidex, Taxotele®, AB VD, Avicin, Abagobomab, Acridin carboxamide, Adekatumab, 17-N-allylamino-17-demethoxygeldanamycin, alfaradine, albosidib, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, amonapid, anthracendione, anti-CD22 immunotoxin, anti-tumor drugs, anti-tumor drugs, anti-tumor-forming herbs, apazikuon, atyprimod, azathioprine, velotecan, bentamustin, BIBW 2992, viricodar, brostallisin, briostatin, butionine sulfoxymine, CBV (chemotherapy), caliculin, cell-cycle nonspecific anti-tumor agents, dichloroacetic acid, discodermolid, elsamituric acid, enositavin, epotylone, eribulin, evelobus, exatecan, exasulind, peruginol, porodecine, phosphestrol, ICE chemotherapy, IT- 101, Imexson, imiquimode, indolocarbazole, lanyquidar, llanicidor, llothaxel, lenalidomide, lukantone, rutotecan, mapopamide, mitozolomide, napoxidine, nedapatoplastin, orthataxel, PAC1, faupau, pixantron, proteasome inhibitor, RebeccaMycin, leciquiquimode, rubitecan, SN-38, salinosporamide A, salinosporamide A, sapacitabin, Stanford V, Swainsonin, Tallaporphin, Tariquidar, Tegapur-Urasil, Temodar, Temodar, Temailcell, Triplelatintetranitrate, Tris (2-chloroethyl)amine, Troxacitabin, Uramustin, Bodymezan, Vinflunin, ZD6126, or Zozoquidar.
[0081] Dislcosed herein are methods of using the compound or pharmaceutical composition provided herein in combination with radiation therapy to inhibit abnormal cell growth or treat hyperproliferative disorders in mammals. Techniques for administering radiation therapy are known in the field, and these techniques can be used in the combination therapy described herein. The administration of the compound disclosed herein in this combination therapy can be determined as described herein.
[0082] Radiation therapy can be administered through one or a combination of several methods including, but not limited to, external-beam therapy, radiation therapy, implant radiation, stereotactic radiation, whole-body radiation surgery, radiation therapy, and permanent or temporary intratissue brachytherapy.
[0083] Radiation therapy refers to radiation therapy delivered by spatially localized radioactive substances inserted into the body at or near tumors or other proliferative tissue disease sites. The term intends to include, without limitation, exposure to radioactive isotopes (e.g., At-2111, 1-131, 1-125, Y-90, Re-186, Re-188, Sm-153, Bi-212, P-32, and Lu's radioactive isotopes).
[0084] Suitable radiation sources for use as cell conditioners include both solid and liquid. As a non-limiting example, the radiation source can be radionuclides, for example, 1-125, 1-131, Yb-169, Ir- 192, as a solid source, 1125, or other radionuclides that emit photons, beta particles, gamma radiation, or other therapeutic rays. The radioactive material can also be a fluid made from a solution of any radionuclide(s), for example, a solution of 1-125 or 1-131, or the radioactive fluid can be produced using a slurry of a suitable fluid containing small particles of solid radionuclides, for example Au- 198, Y-90. Moreover, the radionuclide(s) can be embedded in a gel or radioactive microsphere.
[0085] The compound or pharmaceutical composition disclosed herein can be used in combination with an amount of at least one material selected from an anti- angiogenic agent, a signal conversion inhibitor, an anti-proliferative agent, a corresponding inhibitor, or an autophagy inhibitor.
[0086] Anti-angiogenic agents, such as MMP-2 (matrix-metalloproteinase 2) inhibitors, MMP- 9 (matrix-metalloproteinase 9) inhibitors, and COX- 11 (cyclooxygenase 11) inhibitors, can be used together with the compound disclosed herein and the pharmaceutical composition disclosed herein. Anti- angiogenic agents include, for example, rapamycin, temcyrolimus (CCI- 779), epherolimus (RAD001), sorafenib, sunitinib, and bevacizumab. Examples of useful COX-II inhibitors include alecoxib, valdecoxib, and lopocoxib.
[0087] Examples of metalloproteinase inhibitors are WO96 / 33172, WO96 / 27583, EP0818442, EP1004578, WO98 / 07697, WO98 / 03516, WO98 / 34918, WO98 / 3495, WO98 / 33768, WO98 / 30566, European Patent Publication 606046, European Patent Publication 931 788, W090 / 05719, WO99 / 52910, WO99 / 52889, WO99 / 29667, WO1999007675, EP178675, EP1181017, US20090012085, US Patent Publication US586349, US Patent Publication US5861 510, and EP0780386, all of which are incorporated herein by reference in their entirety. In some embodiments, the MMP-2 and MMP-9 inhibitors are those with little or no activity to inhibit MMP-1.
[0088] In some embodiments, MMP-2 and / or AMP-9 can be selectively inhibited compared to other matrix-metalloproteinases (i.e., MAP-1, MMP-3, MMP-4, MMP-5, MMP-6, MMP-7, MMP-8, MMP-10, MMP-11, MMP-12, and MMP-13).
[0089] Such compounds also include other anti-tumor agents, such as acemanan, aclarubicin, aldesleukin, alletuzumab, alitretinoin, altretamine, amipostin, aminolebulic acid, amlubicin, amnoxacrin, anagrid, anastrozole, ancer (ANCER), anestim, arglabin (ARGLABIN), arglabin (ARGLABIN), arglabin, arglabin trioxidin, BAM 002 (Novelos), bexarotene, bicalutamide, broxuridine, capecitavin, selmoleukin, setorelix, clathrimazole, cithrimazole, citharabin oxphosphate, DA 3030 (DongA), daclizumab, denileukline, dexrajoxane, dilazep, docetaxel, docosanol, doxifluriperol, doxifluridine, doxifluricin, bromocryptin, carmustin, sitarabin, fluorouracil, HIT diclophenacin, interferon alpha, downorubicin, doxirubicin, tretinoin, edelophoromab, epiplorin, epoethin, etoposide phosphate, exemestan, exesulind, padrozol, phynastim, pynastrid, fludarabin phosphate, formestan, portemustin, nitricol, gemcitabin, gemtuzumab ozogamysin, gimeracil / teracil / tegasilPur combinations, glycopine, gocerelin, heptaplatin, human chorionic gonadotropic hormone, human fetal alpha fetal protein, ibandron acid, dirubicin, (imiquimode, interferon alpha, natural interferon alpha, interferon alpha-2, interferon alpha-2, interferon alpha2a, interferon alpha-2b, interferon alpha-Nl, interferon alpha-n3, interferon alpha- 1, natural interferon alpha, interferon beta- la, interferon beta- lb, interferon beta- lb, interferon gamma, natural phosphorus Terperon gamma- la, interferon gamma-lb, interleukin- 1 beta, lobenguan, irinotecan, irsogladin, lanreotide, LC 9018 (Yakult), leflunomide, renograth team, lentinansulfate, retrozol, leukocyte alpha interferon, leuprorelin, rebamisol + fluorouracil, riaozol, lobaplatin, lonidamine, lobastatin, masoprochol, melarsoprol, methoclopramide, mifepristone, miltefosin, mirimos team, mismatch double-stranded RNA, mitoguazone, mitoractol, mitoxanthron, molgramos team, nafarellin, naloxone + pentazocin, natoglast team, nedaplatin, nilutamide, noscarpin, novel erythrocyte-stimulating protein, NSC 631570 octreotide, oprelvequin, osaterone, oxaliplatin, paclitaxel, paklitaxel, pegaspargaase,peginterferon alpha- 2b, pentose polysulfate sodium, pentostatin, fiscibanyl, pirarubicin, rabbit anti-thymocyte polyclonal antibody, polyethylene glycol interferon alpha-2a, porpimer sodium, raloxifel, raltrexed, rasburicaid, rhenium Re 186 ethidronate, RII retinamide, rituximab, romurtis samarium (153 Sm) Lexidronam, sargramos team, sijo pyran, bovine tribal acid, sonermin, strontium chloride-89, suramin, tasonermin, tazarotene, tegapur, temoporphine, temozolomide, teniposide, tetrachlorodecaoxide, thalidomide, thymalpacin, tyrotropin alpha, topotecan, toremifen, tocitumab-iod 131, trastuzumab, treotizumab, treotinine, trimetrexate, tryptorelin, natural tumor necrosis factor alpha, uvenimex, bladder cancer vaccine, maruyama vaccine, melanoma lysate vaccine, valubicin, birteporphine, vinaurevin, virulizin (VIURLIZIN), ginostatin stymala, or zoledronic acid; abarellix; AE 941 (Aeterna), ambamustin, antisense oligonucleotide, bcl-2 (Genta), APC 8015 (Dendreon), cetuximab, decitabin, dexaminoglutamide, diazicuon, EL 532 (Elan), 800 (Endorcheche), enyluracil, etanidazole, penretinid, pyltynid, pylgd Rastim SD01 (Amgen), Fulvestant, Galocitavin, Gastrin 17 Immunogen, HLA-B7 gene therapy (Vical), granulocyte macrophage colonystimulating factor, histamine dihydrochloride, ibritumab tiuksetan, ilomastat, IM 862 (Cytran), interleukin-2, ifproxyfen, LDI 200 (Milkhaus), Leridis team, lintuzumab, CA 125 MAb (Biomira), cancer MAb (Japan Pharmaceutical Development), HER-2 and Fc MAb (Medarex), and idiotype 105 AD7 (CRC Technology), idio Type CEA MAb (Trilex), LYM-l-iodine 131 MAb (Techniclone), Polymorphic Epithelial Mucin-Yttrium 90 MAb (Antisoma), Marimastat, Menogaryl, Mitumomomab, Motexapin Gadolinium, MX 6 (Galderma), Nellabin, Nola Trexic De, P30 Protein, Pegvisomant, Pemetrexed, Porphyromycin, Prinomastat, RL 0903 (Shire), Rubitecan, Satraplatin, Sodium Phenylacetate, SRL 172 (SR Pharma), SU 5416 (SUGEN), TA 077 (Tanabe), tetratiomolybdate, thaliblastin, thromboietin, tin ethyl ethiopurine, tyrapazamine, cancer vaccine (Biomira), melanoma vaccine (New York University), melanoma Medical College, viral melanoma cell lysate vaccine (Royal New Castle Hospital), or co-treatment with Valspodar. The compound disclosed herein can be further used together with a VEGFR inhibitor.
[0090] Other compounds described in the following patent publications can be used in combination therapy: US 6,258,812, US 2003 / 0105091, W001 / 37820, US 6,235,764, WO01 / 32651, US 6,630,500, US 6,515,004, US 6,713,485, US 5,521,184, US 5,770,599, US 5,747,498, W002 / 68406, W002 / 66470, W002 / 55501, W004 / 05279, W004 / 07458, W004 / 09784, W002 / 59110, W099 / 45009, WO00 / 59509, WO99 / 61422, US 5,990,141, WO00 / 12089, and WO00 / 02871, all incorporated by reference herein in their entirety.
[0091] In some embodiments, the combination includes the composition disclosed herein in combination with at least one anti-angiogenic agent. Agents include, but are not limited to, chemical compositions prepared by in vitro synthesis, antibodies, antigen-binding regions, radionuclides, combinations thereof, and conjugates.
[0092] Agents can be agents, antagonists, allosteric regulators, toxins, or more generally act to inhibit or stimulate their targets (e.g., receptor or enzyme activation or inhibition), thereby promoting cell death or inhibiting cell growth. Exemplary anti-angiogenic agents include Erbitux (ERBITUX™) (IMC-C225), KDR (kinase domain receptor) inhibitory agents (e.g., antibody and antigen binding regions that specifically bind to kinase domain receptors), anti- VEGF agents (e.g., antibodies or antigen binding regions that specifically bind to VEGF, or soluble VEGF receptors, or ligand binding regions thereof), such as Avastin (AVASTIN™) or VEGF-TRAP™, and anti-VEGF receptor agents (e.g., antibody or antigen binding regions that specifically bind to them), EGFR inhibitory agents (e.g., antibody or antigen binding regions that specifically bind to them), e.g., Vectibix (Vectibix), Iresa (IRESSA™) (Zepitinib), TARCEVA™) (eerlotinib), anti-Angl and anti-Ang2 agents (e.g., antibody or antigen binding regions that specifically bind to or their receptors, such as Tie2 / Tek), and anti-Tie2 kinase inhibitory agents (e.g., antibody or antigen binding regions that specifically bind to Tie2 / Tek). The pharmaceutical composition disclosed herein can also include one or more agents (e.g., antibodies, antigen-binding regions, or soluble receptors) that specifically bind to growth factors and inhibit their activity, such as antagonists of hepatocellular growth factors (also known as HGF, scattering factors), and antibodies or antigen-binding regions that specifically bind to their receptor "c-met."
[0093] Other anti- angiogenic agents include Campath, IL-8, B-FGF, Tek antagonist (Ceretti, etc.), U.S. Patent Publication No. 2003 / 0162712; U.S. Patent Publication No. 6,413,932), anti- TWEAK agent (e.g., specifically binding antibody or antigen binding region, or soluble TWEAK receptor antagonist; Wiley, see U.S. Patent No. 6,727,225), ADAM Disintegrin domains (Fanslow et al., U.S. Patent Publication No. 2002 / 0042368) that counteract binding to ligands, specifically binding anti-eph receptors and / or anti-ephrin antibodies or antigen binding regions (U.S. Patent No. 5,981,245; 5,728,813; 5,969,110; 6,596,852; 6,232,447; 6,057,124 and its patent family members), as well as anti-PDGF-BB antagonists (e.g., antibody or antigen binding regions that specifically bind to PDGF-BB ligands), and PDGFR kinase inhibition agents (e.g., antibody or antigen binding regions that specifically bind to PDGF-BB ligands).
[0094] Additional anti-angiogenic agents / anti-tumor agents include: SD-7784 (Pfizer, U.S.- based); Silengitide (Merck KGaA, German-based, EPO 770622); Gilead Sciences, U.S. -based);Alphastatin (BioActa, U.K.-based); M-PGA (Celgene, U.S.-based, U.S. -based, U.S. 5712291); Iromastat (Arriva, U.S. -based, U.S. 5892112); Eimaxanib (Pfizer, U.S. -based, U.S. -based, 5792783); Novartis, Switzerland; 2-methoxyestradiol (Entremed, U.S. -based); TEC ELL- 12 (Elan, Ireland-based); Anekortab acetate (Alcon, U.S. -based); Alpha-D148 Mab (Amgen, U.S.- based), CEP-7055 (Cephalon, U.S. -based), anti-Vn Mab (Crucell, Netherlands-based) DAC: Anti-angiogenic (ConjuChem, Canada-based), Angiocidin (InKine Pharmaceutical, U.S.- based); KM-2550 (Kyowa Hakko, based in Japan); SU-0879 (Pfizer, based in the United States); CGP-79787 (Novartis, based in Switzerland, EP 970070); ARGENT technology (Ariad, based in the United States); YIGSR-Stealth (Johnson & Johnson, based in the United States); Fibrinogen-E fragments (BioActa, based in the United Kingdom); Angiogenesis inhibitors (Trigen, based in the United Kingdom); TBC-1635 (Incidential Pharmaceuticals, based in the United States); SC-236 (Pfizer, based in the United States); ABT-567 (Abbott, based in the United States); Metastatin (Entremed, based in the United States); Tripp, angiogenesis inhibitors (Sosei, based in Sweden); Ma spin (Sosei, based in Japan); 2-Metoxie Stradiol (IVAX, based in the United States); ER-68203-00 (IVAX, based in the United States); Benefins (Lane Labs, based in the United States); Tz-93 (Tsumura, based in Japan); TAN- 1120 (Takeda, based in Japan); FR111142 (Fujisawa, based in Japan, JP 02233610); Platelet Factor 4 (Repligen, based in the United States, EP 407122); Vascular Endothelial Growth Factor Antagonist (Borean, based in Denmark); Bevacizumab (pINN, based in the United States); Angiogenesis inhibitor (SUGEN, based in the United States); XL 784 (Exelixis, based in the United States); XL 647 (Exelixis, based in the United States); MAb, Alpha5beta3 Integrin, Generation 2 (Applied Molecular Evolution, based in the United States and Medlmmune, based in the United States); Gene Therapy, Retinopathy (Oxford BioMedica, based in the United Kingdom); Enstaurine Hydrochloride (USAN) (Lilly, based in the United States); CEP 7055 (Cephalon, based in the United States and Sanofi Synthelabo, based in France); BC 1 (Genoa Institute of Cancer Research, based in Italy); Angiogenesis inhibitor (Alchemia, based in Australia); VEGF antagonists (Regeneron, based in the United States); rBPI 21 and BPI-derived anti-angioplasts (XOMA, based in the United States); PI 88 (Progen, based in Australia); Silenced (pINN, based in Germany; Munich Technical University, Germany; Scripps Clinical and Research Foundation, based in the United States); Cetuximab (INN, based in France); AVE 8062 (Ajinomoto, based in Japan); AS 1404 (Cancer Research Laboratory, based in New Zealand); SG 292 (Telios, based in the United States); Endostatin (Boston Children's Hospital, based in the United States); ATN 161 (Attenuon, based in the United States); ANGISTATIN (Boston Children's Hospital, based in the United States); 2-methoxy Systradiol (Boston Children'sHospital, based in the United States); ZD 6474 (AstraZeneca, based in the United Kingdom); ZD 6126 (Angiogen Pharmaceuticals, U.K.); PPI 2458 (Praecis, U.S. -based); AZD 9935 (Astra Zeneca, U.K.-based); AZD 2171 (Astra Zeneca, U.K. -based); Batalanib (pINN) (Novartis, Schering AG, Germany-based); Tissue Factor Pathways Inhibitor (EntreMed, U.S. -based); Pegaptanib (Pinn, U.S. -based); Gilead Sciences; Xanthorrhizol (Yonsei University, South Korea-based); Vaccine, Gene-based, VEGF-2 (Scripps Clinic and Research Foundation, U.S.- based); SPV5.2 (Supratek, Canada-based); SDX 103 (University of California at San Diego, U.S. -based); PX 478 (ProlX, U.S. -based); Metastatin (METASTATIN, U.S. -based); Troponin I (Harvard University, U.S.-based); SU 6668 (SUGEN, U.S.-based); OXI 4503 (OXiGEN, U.S. -based); o-Guanidine (Dimensional Pharmaceuticals, U.S. -based);
[0095] Motuforamine C (British Columbia University, Canada); CDP 791 (Celltech Group, UK); Artifrimode (pINN) (GlaxoSmithKline, UK); E7820 (Eisai, Japan); CYC381 (Harvard University, based in the United States); AE 941 (Aeterna, based in Canada); Vaccine, Vascularization (EntreMed, based in the United States); Eurokinase plasminogen activator inhibitor (Dendreon, based in the United States); oglufanide (pINN, based in the United States); HIF-1 alpha inhibitor (Xenova, based in the United Kingdom); CEP 5214 (Cephalon, based in the United Kingdom); BAY RES 2622 (Bayer, based in Germany); Angiocidin (InKine, based in the United States); A6 (Angstrom, based in the United States); KR 31372 (Korea Research Institute of Chemical Technology, based in the United States); GW 2286 (GlaxoSmithKline, based in the United Kingdom); EHT 0101 (ExonHit, based in France); CP 868596 (Pfizer, based in the United States); CP 564959 (OSI, based in the United States); CP 547632 (Pfizer, based in the United States); 786034 (GlaxoSmithKline, based in the United Kingdom); KRN 633 (Kirin Brewery, based in Japan); Drug delivery systems, guided, 2-methoxyestradiol (EntreMed, U.S. -based); anginex (Maastricht University, Netherlands-based, and Minnesota University, U.S. -based); ABT 510 (Abbott, U.S. -based); AAL 993 (Novartis, Switzerlandbased); VEGI (ProteomTech, U.S. -based); National Institute on Aging, U.S. -based); SU 11248 (Pfizer, U.S. -based and SUGEN-based); ABT 518 (Abbott, U.S. -based); YH16 (Yantai Wongchang, China-based); S-3APG (Boston Children's Hospital, U.S. -based and EntreMed, U.S. -based); MAb, KDR (ImClon Systems, U.S. -based); MAb, Alpha5 Betal (Protein Design, based in the United States); KDR kinase inhibitors (Celltech Group, based in the United Kingdom, and Johnson & Johnson, based in the United States); GFB 116 (South Florida University, based in the United States and Yale University, based in the United States); CS 706 (Sankyo, based in Japan); Combretastatin A4 Prodrug (Arizona State University, based in the United States); Condroitinase AC (IBEX, based in Canada); BAY RES 2690 (Bayer, based inGermany); AGM 1470 (Harvard University, based in the United States, Takeda, based in Japan, and TAP, based in the United States); AG 13925 (Agouron, based in the United States); Tetra- Thiomolybday(University of Michigan based in the United States); GCS 100 (Wayne State University, based in the United States) CV 247 (Ivy Medical, based in the United Kingdom); CKD 732 (Chong Kun Dang, based in South Korea); MAb, vascular endothelial growth factor (Xenova, based in the United Kingdom); irsogladine (INN, based in Japan); RG 13577 (Aventis, based in France); WX 360 (Wilex, based in Germany); squalamine (pINN, based in the United States); RPI 4610 (Sima, based in the United States); cancer therapy drug (Marinova, based in Australia); heparanase inhibitor (InSight, Israel); KL 3106 (Kolon, based in South Korea); Honokiol (Emory University, based in the United States); ZK CDK (Scheering AG, based in Germany); ZK Angio (Scheering AG, based in Germany); ZK 229561 (Novartis, Swiss, based in Switzerland, and Scering AG, based in Germany); XMP 300 (XOMA, based in the United States); VGA 1102 (Taiso, based in Japan); VEGF receptor modulators (Pharmacopeia, based in the United States); VE-Cadherin-2 antagonists (ImClon Systems, based in the United States); Vasostatin (National Institutes of Health, based in the United States); Vaccines, Flk-1 (ImClon Systems, based in the United States); TZ 93 (Tsumura, based in Japan); TumStatin (Beth Israel Hospital, based in the United States); Head-type Soluble FLT 1 (Vascular Endothelial Growth Factor Receptor 1) (Merck & Co, based in the United States); Tie-2 ligand (Regeneron, based in the United States); and Trombospondin 1 inhibitors (Allegheny Health, Education and Research Foundation, based in the United States).
[0096] Autophagy inhibitors include chloroquine, 3-methyladenine, hydroxychloroquine (Plaquenil™), bafilomycin Al, 5-amino-4-imidazole carboxamide riboside (AICAR), okadaic acid, and autophagy-inhibiting algal toxins that inhibit type 2A or type lof protein phosphatases, analogs of cAMP, and drugs that increase cAMP levels such as adenosine, LY204002, N6- mercaptopurine riboside, and vinblastine, but not limited to . In addition, antisense antibodies that inhibit the expression of proteins including, but not limited to, ATG5 (involved in autophagy) Antisense or siRNAs that inhibit the expression of proteins, including but not limited to ATG5 (involved in autophagy), can also be used. Additional pharmaceutically active compounds / agents that can be used in the treatment of cancer and used in combination with one or more of the compounds disclosed herein include: epoethin alpha; d'arbefoethin alpha; panitumumumab; pegfilgrasteam; palifermin;pilgrasteam; denosumab;anestim; AMG 102; AMG 386; AMG 479; AMG 655; AMG 745; AMG 951; and AMG 706, or an acceptable salt under its constraints.
[0097] In some embodiments, the compositions provided herein are co-administered in combination with a chemotherapy agent. Suitable chemotherapy agents include natural products such as vinca alkaloids (e.g., vincablastin, vincristin, and vinorelvin), paclitaxel, epipyphylotoxin (e.g., ethophoside and teniphoside), antibiotics (e.g., dactinomycin (actinomycin D), downorubicin, doxorubicin, and dirubicin), anthracycline, mitoxanthron, bleomycin, flickamycin (mitramycin), mitomycin, enzymes (e.g., L-asparaginase, which metabolizes L-asparagine systematically and deprives cells that do not have the ability to synthesize their own asparagine), antiplatelet drugs, anti-proliferative / anti-microbial alkylating agents, e.g., nitrogen mustard (e.g., metholletamine, cyclophosphamide and analogs, melphalan, and chlorambucyl), ethyleneimine and methylmelamine (e.g., hexamethylmelamine and thiotepa), CDK inhibitors (e.g., celliclip, UCN-01, P1446A-05, and chlorambucyl), PD-0332991, dinaclip, P27-00, AT-7519, RGB286638, and SCH727965), sulfonic acid alkyl (e.g., subplate), nitrosurea (e.g., carmustin (BCNU) and analogs and streptozocin), tragenes-dacarbaginin (DTIC), anti-proliferative / anti-mutagenic antimicrobial agents, e.g., folate analogs (e.g., methotrexate), pyridine analogs (e.g., fluorouracil, floxiridine, and cytarabin), purine analogs and related inhibitors (e.g., mercaptopurin, thioguanine, pentostatin, and 2-chlorodeoxyadenosine), aromatase inhibitors (e.g., anastrozole, exemestane, and retrozole), and platinum ligands (e.g., cisplatin and carboplatin), procarbazine, hydroxyurea, mitotane, aminoglutethimide, histone deacetylase (e.g., tricostatin, sodium butyrate, apisidan, suberoyl anilid hydroamic acid, vorinostat, vorinostat, and retrozol), platinum ligand (e.g., cisplatin and carboplatin), LBH 589, romidepsin, ACY-1215, and panovinostat), mTor inhibitors (e.g., temsirolimus, epherolimus, lidapolimus, and sirolymus), KSP (Eg5) inhibitors (e.g., Array 520), DNA binders (e.g., Zalipsis), PI3K delta inhibitors (e.g., GS-1101 and TGR-1202), PI3K delta and gamma inhibitors (e.g., CAL-130), multi-kinase inhibitors (e.g., TG02 and sorafenib), hormones (e.g., estrogen), and hormone agonists (e.g., LHRH) actuators (e.g., highcerelin, leuprolid, and tryptorelin), BAFF-neutralizing antibodies (e.g., LY2127399), IK inhibitors, p38MAPK inhibitors, p38MAPK inhibitors, anti-IL-6 (e.g., CNTO328), telomerase inhibitors (e.g., GRN 163L), aurora kinase inhibitors (e.g., MLN8237), cell surface inhibitors (e.g., MLN8237), cell surface kinase inhibitors (e.g., MLN8237)
[0098] Monoclonal antibodies (e.g., anti-CD38 (HUMAX-CD38), anti-CSl (e.g., elotuzumab), HSP90 inhibitors (e.g., 17 AAG and KOS 953), P13K / Akt inhibitors (e.g., periposin), Akt inhibitors (e.g., GSK2141795), PKC inhibitors (e.g., enzastaurine), FTI (e.g., Zarnestra™), anti-CD138 (e.g., BT062), Torcl / 2 specific kinase inhibitors (e.g., INK128), kinase inhibitors (e.g., GS-1101), ER / UPR targeting agents (e.g., MKC-3946), cFMS inhibitors (e.g., ARRY-382), JAK1 / 2 inhibitors (e.g., CYT387), PARP inhibitors (e.g., olaparib and beliparib (ABT- 888), and BCL-2 antagonists can be included in other chemotherapy drugs. Other chemotherapy agents can include mechloretamine, camptocin, ifosfamide, tamoxifen, gemcitabin, nabelvin, sorafenib, or any analog or derivative variant of the above.
[0099] The compounds disclosed herein can also be used in combination with radiation therapy, hormone therapy, surgery and immunotherapy, and these treatments are well known to those skilled in the art. In some embodiments, the pharmaceutical composition provided herein is coadministered with steroids.
[0100] Suitable steroids include 21-acetoxypregenolone, algestone, myosinone, myosinone, beclomethasone, betamethasone, budesonid, chlorofrednisone, chlorobetasol, cloprednol, cortisone, cortisone, cortisone, cortisone, cortibazole, deflazacot, desonid, desoxymethasone, dexamethasone, diplausone, diflucortolone, dipfredate, enoxolone, fluazacot, fluoronid, fluosinone acetonide, fluorocortin butyl, fluorocortin, fluoromethoIone, fluorometholone, fluoromethoIone acetate, flufrednisolone, flurandrenolid, flutikasone propionate, formocortal, halobetasol propionate, halometasone, hydrocortisone, rotefredonate, marzipredon, medrissone, mefrednisone, methylprednisone, momethasone, furoate, prednisol, prednisol, prednisol, prednisol, prednisolone, prednisolone, ethylamino acetate, prednisolone sodium phosphate, prednisone, prednisone, prednisolone, prednisolone, prednisolone, thixocortol, triamcinolone, triamcinolone acetonide, triamcinolone benetonide, triamcinolone hexaacetonide, and salts and / or derivatives thereof are included, but are not limited. In some embodiments, the compounds disclosed herein can also be used in combination with additional pharmaceutical activators that treat nausea. Examples of agents that can be used to treat nausea include: dronabinol; graniset Ron; methoclopramide; ondansetron; and prochlorperazine; or a pharmaceutically acceptable salt thereof.
[0101] The compound or pharmaceutical composition disclosed herein can also be used in combination with a certain amount of one or more substances selected from EGFR inhibitors, MEK inhibitors, PI3K inhibitors, AKT inhibitors, TOR inhibitors, and immunotherapy (including anti-PD-1, anti-PDL-1, anti-CTLA4, anti-LAGl, and anti-OX40 agents, GITR agonists, CAR-T cells, and BiTE). EGFR inhibitors include, but are not limited to, small molecule antagonists, antibody inhibitors, or specific antisense nucleotides or siRNAs. Antibody inhibitors of EGFR that are useful include cetuximab, panitumumab, vectibix, zalutumumab, nimotuzumab, and matuzumab. Small molecule antagonists of EGFR include zepitinib, erlotinib (Tarceva), and most recently, lapatinib (TykerB) (Yan L, et. al., Pharmacogenetics and Pharmacogenomics In Oncology Therapeutic Antibody Development,BioTechniques 2005; 39(4): 565-8)) (Paez J G, et. al., EGFR Mutations In Lung Cancer correlation With Clinical Response To Gefitinib Therapy, Science 2004; 304(5676): 1497-500).
[0102] Non-limiting examples of small molecule EGFR inhibitors include any EGFR inhibitor described in the following patent publication, and all pharmaceutically acceptable salts and solvate of the above EGFR inhibitors: European Patent Application EP 520722 published on December 30, 1992; European Patent Application EP 566226 published on October 20, 1993; PCT International Open WO96 / 33980 published on October 31, 1996; U.S. Patent No. 5,747,498 registered on May 5, 1998; PCT Bureau released on October 3, 1996 Article 96 / 30347; European Patent Application EP 787772 released on August 6, 1997; PCT International Open W097 / 30034 released on August 21, 1997; PCT International Open W097 / 30044 released on August 21, 1997; PCT International Open WO97 / 38994 released on October 23, 1997; 12 PCT International Disclosure WO97 / 49688 released on 31 April 1998; European Patent Application EP 837063 released on 22 April 1998; PCT International Disclosure WO98 / 02434 released on 22 January 1998; PCT International Disclosure WO95 / 19774 released on 27 July 1995; PCT International Disclosure WO95 / 13771 released on 27 July 1997; PCT International Disclosure WO98 / 02437 released on 22 January 1998; PCT International Disclosure WO98 / 02438 released on 22 January 1997; PCT International Disclosure WO97 / 32881 released on 12 September 1997; PCT International Disclosure WO19629652 released on 29 January 1998; PCT International Disclosure WO98 / 33798 released on 6 August 1998; PCT International Disclosure WO97 / 32880 released on 12 September 1997; PCT International Disclosure WO97 / 32880 released on 12 September 1997; European Patent Application EP688880 released on 15 November 1995 EP6881 released on 15 November 19952027; PCT International Released WO97 / 02266 released on January 23, 1997; PCT International Released WO released on July 31, 1997 97 / 27199; PCT International Open WO98 / 07726 released on February 26, 1998; PCT International Open WO96 / 34895 released on September 25, 1997; PCT International Open WO96 / 31510 released on October 10, 1996; PCT International Open WO98 / 14449 released on April 9, 1998; PCT International Open WO98 / 14450 released on April 9, 1998; PCT International Open WO95 / 09847 released on April 13, 1995; PCT International Open WO97 / 19065 released on May 29, 1997; PCT International Open WO96 / 19065 released on April 30, 1998 98 / 17662; U.S. Patent No. 5,789,427 registered on August 4, 1998; U.S. PatentNo. 5,650,415 registered on July 22, 1997; U.S. Patent No. 5,656,643 registered on August 12, 1997; PCT International Open WO99 / 35146 disclosed on July 15, 1999; PCT International Open WO99 / 35132 disclosed on February 18, 1999 99 / 07701; and PCT International Disclosure WO92 / 20642, released onNovember 26, 1992. Additional non-limiting examples of small molecule EGFR inhibitors are in the literature (Traxler, P., 1998, Exp. Opin. Then).
[0103] It includes any EGFR inhibitor described in Patents 8(12): 1599- 1625. Antibody-based EGFR inhibitors include any anti-EGFR antibody or antibody fragment capable of partially or completely blocking EGFR activation by its natural ligand. Non-limiting examples of antibody-based EGFR inhibitors include those described in the literature (Modjtahedi, H., et al., 1993, Br. J. Cancer 67:247-253); literature (Teramoto, T., et al., 1996, Cancer 77:639-645); literature (Goldstein et al., 1995, Clin. Cancer Res. 1:1311-1318); literature (Huang, S. M., et al., 1999, Cancer Res. 15:59 (8):1935-40); and literature (Yang, X., et al., 1999, Cancer Res. 59:1236-1243). Therefore, the EGFR inhibitor can be a monoclonal antibody MAb E7.6.3 (Yang, 1999), or MAb C225 (ATCC access number HB8508), or an antibody or antibody fragment having binding specificity thereof. MEK inhibitors include, but are not limited to, CI- 1040, AZD6244, PD318O88, PD938059, PD334581, RDEA119, ARRY-142886, ARRY- 438162, and PD325901.
[0104] PI3K inhibitors include bortmannin, a 17 -hydroxy bortmannin analog described in W 006 / 044453 , 4- [2-( 1 H-indazole-4-yl)-6- [4-(methylsulfonyl)piperazine- 1 - yl]methyl]thieno[3,2-d]pyrimidine-4-yl]morpholine (also known as GDC 0941 and described in PCT Publications W009 / 036,082 and W009 / 055,730), 2-methyl-2-[4-[3-methyl-2-oxo-8- 8-yl](Quin°line-3-yl)-2,3-dihydroimidazo [4,5-c]quinoline- l-yl]phenyl]propionitrile (also known as BEZ 235 or NVP-BEZ 235, described in PCT Publication No. W006 / 122806), (S)- l-(4-(2-(2-aminopyrimidine-5-yl)-7-methyl-4-morpholinotieno[3,2-d]piperazine-6-yl)-2- hydroxypropane-l-on (described in PCT Publication No. W02008 / 070740), LY294002(4- morpholynyl)-8-phenyl-4H-l-benzopyran-4-on), PI 103 hydrochloride (3-[4-(4-(4- morpolynipyrido-[3',2':4,5]Furo[3,2-d]pyrimidine-2-yl]phenol hydrochloride), PIK 75(N’ [( 1 E)-(6-bromodimidazo [ 1 ,2-a]pyridine-3 -yl)methylene] -N,2-dimethyl-5- nitrobenzulfono-hydrazide hydrochloride), PIK 90(7, 8-dimethoxy-2,3-dihydro-imidazo[ 1,2- c]quinazo[l,2-yl]quinazoline-5-yl) phenol hydrochloride), G-nitazoline-5-nitrogenamide), G- nitrogenamide) and PIK 90(7,8-dimethoxy-2,3-dimethoxy-2-dimidazo[l,2-c]quinazoline-5- yl), G-nico tinamide), G-nitinamide)2-(lH-indazole-4-day)-6-(4-methanesulfonyl-piperazine- l-ylmethyl)-4-morpholine-4-yl-thieno[3,2-d]pyrimidine bismecylate) available from DC-0941 bismecylate (DC-0941 -bismecylate), AS-2252424 ((5-(4-fhioro-2-hydroxy-phenyl)-furan-2- yl]-meth-ylidene] -thiazolidine-2,4-dion), and TGX-221 (4-morpholynyl)-9- [1 - (phenylamino)ethyl]-4H-pyrido-[l,2-a]pyrimidine-4-on), Includes, but is not limited to, XL- 765 and XL- 147. Other PI3K inhibitors include, but are not limited to, demethoxy viridine,periposin, CAL101, PX-866, BEZ235, SF1126JNK117, IPL145, BKM120, XL147, XL765, palomide 529, GSK1059615, ZSTK474, PWT33597, IC87114, TG100-115, CAL263, PI-103, GNE-477, CUDC-907, and AEZS-136. AKT inhibitors are Akt-1-1 (suppressed Aktl) (Barnett et al. 2005) Biochem. J., 385 (Pt. 2), 399-408); Akt-1-1, 2 (suppressed Akl and 2) (Barnett et al. 2005) Biochem. J. 385 (Pt. 2), 399-408); API-59CJOme (e.g., literature (Jin et al. 2004) Br. J. Cancer 91, 1808-12); 1-H-imidazo [4, 5-c]pyridinyl compounds (e.g., W005011700); indole- 3-carbinol and its derivatives (e.g., U.S. Patent No. 6,656,963; literature [Sarkar and Li (2004) J Nutr. 134 (12 Suppl), 3493S-3498S); periposin (e.g., interfering with Akt membrane localization; literature (Dasmahapatra et al. (2004) Clin. Cancer Res. 10 (15), 5242-52, 2004); phosphatidylinositol ether lipid analogs (e.g., literature (Gills and Dennis (2004) Expert. Opin. Investig. Drugs 13, 787-97)); and trisiribin (TCN or API-2 or NCI identifier: NSC 154020; literature (Yang et al. (2004) Cancer Res. 64, 4394-9). TOR inhibitors include, but are not limited to, AP-23573, CCI-779, Everolimus, RAD-001, rapamycin, tempsilimus, ATP- competitive TORC1 / TORC2 inhibitors (including, but not limited to, PI- 103, PP242, PP30, and Torin 1).
[0105] Other TOR inhibitors in FKBP12 enhancers; rapamycin and its derivatives (including: CCI-779 (temsirolimus), RAD001 (Everolimus; W09409010) and AP23573; for example, LAPAGO as disclosed in WO98 / 02441 and WOOl / 14387; for example, AP23573, AP23464 or AP23841 ; 40-(2-hydroxy ethyl)rapamycin, 40- [3 -hydroxy (hydroxymethyl)methylpropanoate] - rapamycin (also referred to as CC1779), 40-epi-(tetrazolit)-rapamycin (also referred to as ABT578), 32-deoxorafamycin, 16-pentinyloxy-32(S)-dihydrolafaicin, and other derivatives disclosed in W005005434; U.S. Patent No. 5,258,389, W094 / 0901, WO92 / 05179, U.S. Patent No. 5,118,677, U.S. Patent No. 5,118,678, U.S. Patent No. 5,100,883, U.S. Patent No. 5,151,413, U.S. Patent No. 5,120,842, U.S. Patent No. 5,120,842, U.S. Patent No. 5,118,678, U.S. Patent No. 5,100,883, U.S. Patent No. 5,120,151,413, U.S. Patent No. 5,120,842,413, Other TOR inhibitors in FKBP12 enhancers; rapamycin and its derivatives (including: CCI- 779 (temsirolimus), RAD001 (Everolimus; W09409010) and AP23573; for example, LAPAGO as disclosed in WO98 / 02441 and WOOl / 14387; for example, AP23573, AP23464 or AP23841 ; 40-(2-hydroxy ethyl)rapamycin, 40- [3 -hydroxy (hydroxymethyl)methylpropanoate] - rapamycin (also referred to as CC1779), 40-epi-(tetrazolit)-rapamycin (also referred to as ABT578), 32-deoxorafamycin, 16-pentinyloxy-32(S)-dihydrolafaicin, and other derivatives disclosed in W005005434; U.S. Patent No. 5,258,389, W094 / 090101, WO92 / 05179, U.S. Patent No. 5,118,678, U.S. Patent No. 5,100,883, U.S. Patent No. 5,100,151,413, U.S. Patent No. 5,120,842, WO93 / 1130, WO94 / 02136, WO94 / 02485, WO95 / 14023, WO95 / 14061,WO96 / 16691, WO96 / 41807, WO96 / 41807, WO96 / 41807, and U.S. Patent No. 5,256,790; phosphorus-containing rapamycin derivatives (e.g., W005016252); 4H-l-benzopyran-4-on derivatives (e.g., U.S. runaway number 60 / 528,340). Immunotherapy agents include, but are not limited to, an anti-PDL-1 agent, an anti-CTLA-4 agent, an anti-LAGl agent, and an anti- 0X40 agent. Exemplary anti-PD-1 antibodies and methods of use thereof include, but are not limited to, documents (Goldberg et al., Blood 110(1): 186-192 (2007), Thompson et al., Clin. Cancer Res. 13 (6):1757-1761(2007)), and Korman et al.'s international patent application CT / JP2006 / 309606 (International Open W02006 / 121168 Al), each of which is clearly included as a reference herein. It includes: Yervoy™) (epilimumab) or tremelimumab (for CTLA-4), galiximab (for B7.1), BMS-936558 (for PD-1), MK-3475 (for PD-1), AMP224 (for B7DC), BMS936559 (for B7-H1), MPDL3280A (for B7-H1), MEDI-570 (for ICOS), AMG557 (for B7H2), MGA271 (for B7H3), IMP321 (for B7H3) against), BMS-663513 (for CD137), PF-05082566 (for CD137), CDX-1127 (forCD27), anti-OX40 (for Providence Health Services), huMAbOX40L (for OX40L), ataccept (for TACI), CP870893 (for CD40), lucatumumab (for CD40), dacetumab (for CD40), muromonab-CD3 (for CD3), and ifilumumab (for CTLA-4). Immunotherapy also includes T-cells (e.g., CAR-T cells) generated by genetic engineering and bispecific antibodies (e.g., BiTE).
[0106] GITR agonists include, but are not limited to, GITR fusion proteins and anti-GITR antibodies (e.g., bivalent anti-GITR antibodies), such as GITR fusion proteins (e.g., U.S. Patent No. 6,lll,090box.c, European Patent No. 090505B 1, U.S. Patent No. 8,586,023, PCT International Disclosure W02010 / 003118 and 2011 / 090754), or anti-GITR antibodies (e.g., U.S. Patent No. 7,025,962, European Patent No. 7,812,135, U.S. Patent No. 8,388,967, U.S. Patent No. 8,591,886, European Patent No. EP 1866339, PCT International Disclosure WO20 11 / 028683, PCT International Disclosure WO2013 / 039954, PCT Bureau Open W02005 / 007190, PCT International Open WO2007 / 133822, PCT International Open W02005 / 055808, PCT International Open WO99 / 40196, PCT International Open W02001 / 03720, PCT International Open W02006 / 083289, PCT International Open W02005 / 115451, U.S. Patent No. 7,618,632, and PCT International Open WO2011 / 051726).
[0107] As disclosed herein, a strategy was proposed to develop a novel scheme of a target protein degrader-molecular glue (MG). Our MG strategy aims to target 'undrugable' KRAS G12D and G12V mutations. Small molecules were designed (less than 500 Da) to enhance protein-protein interactions of KRAS mutants and E3 ligases targeting orthostatic sites using the in silico method including Al-based ligand design and molecular dynamics simulation.
[0108] Innate transient interactions between proteins were utilized to translate weak interactions into stronger interactions. Using this strategy, MG molecules for KRAS G12D, which lead to the degradation of KRAS G12D in cells, were designed and synthesized. Using this strategy, MG molecules for KRAS G12D that lead to the degradation of KRAS G12D in cells were designed and synthesized. This strategy can be applied to drive proximity to any protein target given that 1) their structures are known and 2) the target protein-protein natural transient interactions exhibit at least micromolar Kd.
[0109] Accordingly, the compounds disclosed herein can target KRAS G12D and / or G12V mutations which are difficult to target, and thus can be applied as anticancer drug candidates.EXAMPLES
[0110] Hereinafter, the present invention will be described in more detail with reference to non-limiting embodiments. However, the following examples are described with the intention of illustrating the present invention and the scope of the present invention is not construed as being limited by the following examples.Example 1
[0111] The CaCo-2(ATTC), H1975(CRL-5908), and LS-180(CCL-187) cells were obtained from ATCC, immediately proliferated, and frozen. The vial was thawed and used within a 20- passage. The SNU-407, SNU-1033, and SK-LU-1 cells were purchased from the Cell Line Bank of Korea, immediately proliferated, and then frozen. The vial was thawed and used within a 20-passage. Caco-2 cells were cultured in MEM (Welgene, LM007-07) supplemented with 10% FBS (GenDEPOT, catalog number F0900-050) and 1% antibiotic antifungal solution (Welgene; catalog number LS203-01). H1975, SNU-407, and SNU-1033 cells were cultured in 10% FBS (GenDEPOT; cat. no. F0900-050) and 1% Antibiotic Antimicrobial Solution (Welgene; cat. No. LS203-01) were cultured in RPMI (Welgene, LM011-03) supplemented. SK-LU-1 and LS-180 cells were cultured in 10% FBS (GenDEPOT; cat. no. F0900-050) and 1% Antibiotic Antimicrobial Solution (DMEM; cat. No. LS203-01) were cultured in a supplemented DMEM (Welgene, LM001-05). Cells were washed using PB S (Welgene; cat. no. LB004-02).
[0112] Cells were isolated for subculture using 0.25% Trypsin-EDTA (cat. no. LS015-01). KRAS mouse monoclonal antibodies were purchased from Origin (catalogue number TA801672) and anti-P-actin was purchased from AB Frontier (catalogue number LF- MA20055). 6X His Tag monoclonal antibody (ThermoFisher Scientific, MAI-21315),recombinant human KRAS (mutant G12D) (Abeam, ab268712, 20 ug), CSNK1A1 (T-337, His-tag) human protein (original, AR51430PU-N, 0.5 mg), recombinant human CUL4A / RBX1 / DDB1 / CRBN complex His-tag)(R&D systems, E3-650, 25ug), Recombinant Human Ubiquitin Activating Enzyme(UBEl)(R&D systems, E-305, 25ug), Recombinant Human UbcH5a / UBE2Dl Protein (R&D systems, E2-616, 100 ug), ATP (Sigma-Aldrich, A6419): powder, Ubiquitin-human (Sigma-Aldrich, U550, lyophilized powder, 1 mg), Cy5 Anti-Ubiquitin antibody (Bios, bs-1549-Cy5) PBS (137 mM NaCl, 2.7 mM KC1, 10 mM sodium diphosphate, 2 mM potassium diphosphate, pH 7.4) was purchased from Sigma.Example 22. Materials and Methods2.1. Materials
[0113] CaCo-2 (ATTC), H1975 (CRL-5908) and LS-180 (CCL-187) cells were obtained from ATCC, expanded immediately, and frozen down. Vials were thawed and used within 20 passages. SNU-407, SNU-1033 and SK-LU-1 cells were obtained from Korean Cell Line Bank, expanded immediately, and frozen down. Vials were thawed and used within 20 passages. Caco-2 cells were cultured in MEM (Welgene, LM007-07) supplemented with 10% FBS GenDEPOT; cat. no. F0900-050) and 1% Antibiotic Antimycotic solution (Welgene; cat. No. LS203-01). H1975, SNU-407, SNU-1033 cells were cultured in RPMI (Welgene, LM011-03) supplemented with 10% FBS GenDEPOT; cat. no. F0900-050) and 1% Antibiotic Antimycotic solution (Welgene; cat. No. LS203-01). SK-LU-1 and LS-180 cells were cultured in DMEM (Welgene, LM001-05) supplemented with 10% FBS GenDEPOT; cat. no. F0900-050) and 1% Antibiotic Antimycotic solution (Welgene; cat. No. LS203-01). PBS (Welgene; cat. no. LB004- 02) was used to wash cells and 0.25% Trypsin-EDTA (Welgene; cat. no. LSO 15-01) was used to detach cells for passaging. KRAS Mouse Monoclonal Antibody was purchased from Origene (cat. no. TA801672), anti-P-actin was purchased from AB Frontier (cat. no. LF-MA20055). 6X His Tag Monoclonal Antibody (ThermoFisher Scientific, MAI-21315), Recombinant Human KRAS (mutated G12D) (Abeam, ab268712, 20 ug), CSNKlAl(T-337, His-tag) human protein (origene, AR51430PU-N, 0.5 mg), Recombinant Human CUL4A / RBX1 / DDB 1 / CRBN Complex His-tag) (R&D systems, E3-650, 25 ug),. Recombinant Human Ubiquitin Activating Enzyme (UBE1) (R&D systems, E-305, 25 ug), Recombinant Human UbcH5a / UBE2Dl Protein (R&D systems, E2-616, 100 ug), ATP (Sigma-Aldrich, A6419) : powder, Ubiquitin- human (Sigma- Aldrich, U550, lyophilized powder, Img), Cy5 Anti-Ubiquitin antibody (Bioss,bs-1549-Cy5) PBS (137 mM NaCl, 2.7 mM KC1, 10 mM sodium phosphate dibasic, 2 mM potassium phosphate monobasic, pH 7.4).2.2. Methods2.2.1. In silico design of a molecular glue using an Orthosteric Approach
[0114] A combination of proprietary and open- source software were used to achieve the goal of successfully designing a novel molecular glue (MG) degrader. Examples of such software include Maestro (by Schrodinger - proprietary), Autodock Vina and NAMD. Our MG degrader strategy primarily involves two main approaches: the orthosteric and allosteric approaches.
[0115] The orthosteric approach to designing novel MG degraders mainly rely on the innate protein-protein interactions (PPI) between two proteins - an E3 ligase and our POI. Electrostatic interactions and geometric factors affect such PPI and even if our POI is not an authentic substrate to our E3 of choice, there would be some degree of PPI between them. Such PPI would not be very stable, being a ‘meta-stable’ complex that will dissociate naturally. Our goal is to design a small molecule ligand that will ideally induce, enhance, or mediate the interaction between the E3 of choice and our POI by inserting itself at the PPI interface, thus transforming the meta-stable complex into a stable protein complex. By doing so, we aim to make our POI the ‘neo-substrate’ of our E3 of choice. The schematic of the entire process is shown by the flowchart in FIGS. 1 and 2.2.2.1.1, Preparation of Structure Files
[0116] Since our strategy is founded on the in silico discovery of MG degraders, an accurate representation of the structures of the proteins involved, is of paramount importance. Generally, all structures are obtained from the Protein Data Bank (PDB) as X-ray diffraction crystallographic data. Our first MG degrader discovery process focused on Cereblon (CRBN, PDB ID: 6H0F) and KRAS G12D (PDB ID: 6GJ7). There structures were downloaded and pre-processed using the protein preparation tool in Maestro. The het states of the proteins were adjusted to pH 7.0-7.3 to reflect the intracellular conditions. Hydrogen bonds were optimized, and restrained minimization was performed by converging heavy atoms to RMSD 0.3A to generate the structures of proteins at the global minima of the energy landscape.2.2.1.2 Simulation of innate PPI
[0117] As mentioned before, our orthosteric strategy relies on the innate PPI between the E3 and POI for the formation of a meta-stable complex. To simulate the formation of such complexin silico, we used the protein-protein docking tool in Maestro. Since we have zero prior information about any PPI between our POI and our E3, we choose not to give any restraints in our protein-protein docking procedure. Probing 70,000 KRAS rotations, we generate 20 best poses, ranked according to free energy of interaction. The poses are rejected if the dissociation constant Kd of the best-scoring PPI is greater than the micromolar scale (any PPI at the Kd of millimolar scale is non-interacting), and the visual inspection of the poses generated, we removed any ‘anomalous’ poses, using the best-ranked pose as a reference. Here, anomalous pose indicates that the POI docks to the E3 at a completely different site when compared with the reference pose. After the removal of anomalies, the representative pose is then selected, using the Boltzmann weighting with the parameter being the free energy of interaction. The weighted representative pose is most likely to reflect the structure of the meta-stable complex created by the actual innate PPI.2.2.1.3 Drug fragment generation
[0118] We then use the pharmacophore tool in Maestro in order to generate a suitable pharmacophore hypothesis at the protein-protein interface as found above. Afterwards, we suggest suitable fragment ‘seed’ based on the pharmacophore analysis. Such fragment is utilized for the de novo synthesis.2.2.1.4 De novo synthesis
[0119] The fragment generated per aforementioned process is carried forward to the de novo synthesis of our MG degrader. Using LEA3D server and our hand-coded algorithms, we utilize a generative genetic algorithm to find a hit molecule. We confine the search space of the algorithm to a narrow pocket created by the innate PPI between our two proteins. Using the fragment seed and using Lipinski’s Rule as filters, the generative algorithm generates random mutant molecules from the initial molecule to form a population. Each member of the population is docked to the PPI interface of our simulated complex, and the best-docking structure survives. The best structure now becomes the new initial structure, and the entire process is cycled until we reach convergence. For the complex between KRAS and CRBN, a search space of 15 A at the centroid of the PPI interface was used. Each population was set to a size of 50 molecules, and the algorithm was executed for a maximum of 40 generations. However, we observed convergence for some trials at as early as 16 generations. Our potential candidate MG molecules were selected from numerous trials according to their physicochemical properties and synthetic accessibility.2.2.1.5 Analysis
[0120] The molecule generated with the aforementioned process is then imported to Maestro for further analysis. Preliminary analysis involves the calculation of basic physicochemical properties such as log P (octanol / water partition coefficient), solubility, TPSA (topological polar surface area) etc. These data are stored separately, in case they are urgently needed for any future calculations or simulations. Although in silico docking is performed alongside the genetic algorithm, we choose to re-dock our generated structure into our simulated PPI complex. Using Autodock Vina and Glide, the molecule is docked to the interface PPI complex with the XP (extra-precision) mode. With such re-docking protocol, we wish to make the simulated structure of our protein-ligand ternary complex between the POI, E3 and our potential MG candidate, reflects reality as close as possible. Binding energies are calculated and are used to assess the binding stability of our ligand in the ternary complex.
[0121] Since such static analysis yields no information about the dynamical stability of the ternary complex, we utilize extensive molecular dynamics (MD) simulations. Using Desmond as the main MD softwares, we solvate our ternary complex in water (SPC water model), with our complex located at the center of a cubic unit cell. The system is minimized and equilibrated to a temperature of 340 K (67 deg.C). We use a unusually high temperature to accelerate the thermal dissociation of the protein complex - survival of the complex under such harsh conditions would guarantee stability at lower temperatures. The production run is run for an average of 10 ns (minimum of 5 ns) . The trajectory of the production run is then visually inspected. RMSD data is obtained and analyzed. The MD simulation of the ternary complex is compared to the MD simulation of the binary complex (without the ligand) as a negative control. The results of the simulations will be discussed in the next section.2.2.2 Synthesis of ethyl (2S)-2-((l-oxo-l-phenylpropan-2-yl) amino)-4-phenylbutanoate
[0122] To a solution of ethyl (S)-2-amino-4-phenylbutanoate hydrochloride (1.0 gram, 4.83 mmol) in anhydrous acetonitrile (10 mL) was added a DIPEA (1.68 mL, 9.66 mmol) and 2- bromo-l-phenylpropan-l-one (873 mg, 4.83 mmol). The reaction mixture was then heated at 80 °C for overnight. Afterwards, it was concentrated and dissolved in ethyl acetate. The solution was washed with H2O and brine, and the organic layer dried over MgSO4, filtered and concentrated. The residue was purified by silica gel chromatography with EOAc : Hex = 1 : 8 eluent to furnish the two isomers of compound as light brownish oil: 261 mg (19%) of upspot and 223 mg (16%) of downspot.2.2.3 In-vitro Ubiquitination Assay using IPS-Chip PPIExplorer
[0123] The 0.2 mg / ml 6X His tag monoclonal antibody was diluted in 30 % glycerol in 1 X PBS, pH 7.4, was spotted onto the IPS-Chip for 16 h at 4°C. After washing third with 0.1 % PBST for 5 min and drying under N2 gas, and then blocked with 5 % BSA for 1 h at room temperature. The chip was washed 3 times with PBST and dried. Afterward, Ligand proteins of Various concentration (Recombinant Human KRAS G12D and CSNK1A1) were immobilized onto the chip for 2 h at 37 °C. It was rinsed in PBST and distilled water and dried under N2 gas. E1-E3 complexes (El, E2, E3, ubiquitin and ATP) diluted in 30% glycerol PBS and two types of molecular glue (06061-1 or 06061-2) were made at twice the desired concentration. The E1-E2-E3 complex was mixed in a 1:1 ratio with 06061-1 or 06061-2 and incubated at 25 °C for 1 h. The mixtures were loaded by 1 □! onto the chip for 1 h at 37 °C. After rinsing with PBST and distilled water, an Anti-Ubiquitin Antibody labeled with Cy5, diluted to 1:100 with 30 % glycerol in PBS, was applied to the chip was dried in a stream of N2 gas. To detect polyubiquitination signals, the chip was scanned using a GenePix Pro 6.0 (Axon Instruments, CA, USA), and the data analyzed with an Origin 6.1 (Originlab, MA, USA).2.2.4 Western blot analysis for KRAS Degradation
[0124] 2.0 x 105cells were seeded into 6-well plates (SPL; cat. no. 30006). The next day, media was removed, and cells were treated with 0, 1, 5, 10, 50, 100 pM KRAS-MG in serum free media. For 24h,48h, and 72h. Cells were lysed using a RIPA buffer and clarified at 21,000 x g for 15 min at 4 °C. Protein concentration of the supernatant was measured using a BCAreagent. (Thermofisher; cat. no. 23225) incubated at 37°C for 30 mins. For each sample, equal amounts of protein were denatured and fractionated by Novex Wedge Well 4-20% Tris-Glycine Mini Gels (Invitrogen cat. no. XP04205BOX), and then transferred onto a Immobilon-PVDF Membrane membranes (Merck, cat.no. IPVH00010) at 80 V for 1 h at 4°C. Membranes were blocked by placing them in a 5% BSA in Tris-buffered saline with Tween-20 (TBST; 20 mM Tris, 150 mM NaCl, 0.1% Tween-20) for Ih. Membranes were then incubated overnight at 4 °C with primary antibodies against KRAS (1:1000, invitrogen:#703345), GAPDH (1:2000, Cell signaling #2118). After three washes with TBST, membranes were incubated with the appropriate HRP-conjugated secondary antibodies ( 1:1000, KwikQuant#R1006) for Ihour RT. After three washing. Detection of bound antibodies was carried out using ECL reagents (KwikQuant# R1004) and bands were detected by ATTO Luminograph III Lite. The intensityof the KRAS band was quantified using ImageJ software and normalized to the intensity of GAPDH band.2.2.5 Cell-based Viability Assay
[0125] Cells were seeded into 96-well plates at a density of 2.0 x 103cells / well and incubated with the indicated concentrations of with 0, 1.6, 3.1, 6.3, 12.5, 25, 50 pM KRAS-MG for 72 h.
[0126] Viable cells converted the MTS to its colored formazan derivative, which was quantitated by measuring absorbance at 450 nm using a Micro Plate Reader (Molecular devices). Dose response curves were generated by fitting the data to an inhibitor vs. dose response non-linear regression using GraphPad Prism 7.2.2.6 Ternary complex assay of PPI using a SPR analytical system
[0127] The iClubio-Mini SPR instrument (iClubio) was used for performing protein binding kinetics analysis. The instrument was calibrated and set up according to the manufacturer's instructions. Prior to the experiment, the system was primed with running buffer (PBS). NanoGels Sensor Chip Preparation
[0128] A bare Gold sensor chip (iClubio Corporation) was selected for the immobilization of the ligand. The sensor chip was cleaned following the manufacturer's instructions to remove any contaminants. The surface of the sensor chip was activated using a 10 mM Cysteamine as recommended by the Korea University.
[0129] The injection was performed at a flow rate and for a contact time according to the Korea University Stem cell Lab guidelines. Surface Plasmon Resonance (SPR) analyses were performed using an iMSPR-mini (iCluebio, Seongnam-si, Korea) equipped with two Flow cells, one of which was used as the measurement {06061+ CRBN + KRAS(G12D) in IX PBS} flow cell and the other was used as the reference cell (CRBN + KRAS(G12D) without 06061 in IX PBS). All protein samples (KRAS G12D & CRBN) were diluted in PBS buffer. It was used as the running buffer. After loading the preactivated sensor chip onto the SPR device, the Ni- NTA-functionalized nanogels (10 mM Na, Na- bis(carboxymethyl)-L-lysine hydrate solution in PBS (90 sec, flow rate of 20 Dl / min) was introduced into the surface of the sensor chip for immobilization by electrostatic interactions, and unreacted Ni-NTA-functionalized nanogels (10 mM Na, Na- bis(carboxymethyl)-L-lysine hydrate solution) were removed by flowing the running buffer for 5 min. For the measurement cells, the 1:1:1 Mixtures { 100 nM of the KRAS G12D protein + 100 nM of the CRBN + Various concentration (2000 nM, 200 nM, 100 nM) of the 06061 } injected for 4 min, respectively, whereas the Mixtures (100 nM of the KRAS G12Dprotein + 100 nM of the CRBN without 06061 + PBS) was injected into the reference cells. To facilitate dissociation, running buffer (IX PBS) was injected into both cells after reaching a near-equilibrium state. The sensorgrams were recorded using the embedded software imSPR- mini v 1.1.0.
[0130] The obtained sensorgrams were analyzed using the Tracedraw software for data analysis. The binding sensorgrams were estimated for each sample using the obtained reference - subtracted sensorgrams representing that of flow cell 1 (Measurement cells) minus that of flow cell 2 (Reference cells) The data were fitted to appropriate binding models (e.g., 1:1 Langmuir binding model) to determine kinetic parameters including the association rate constant (ka), dissociation rate constant (kd), and equilibrium dissociation constant (KD). Rmax, Kon, Koff, tl / 2 and dissociation constants (KD) were estimated for the sensorgrams using an appropriate binding model (e.g., 1:1 Langmuir binding model).2.2.7. In vivo tumor-bearing Xenograft assay
[0131] We have conducted the in vivo tumor growth assay using AsPC-1 pancreatic cancer cell-implanted xenograft animals by requesting Eins solution (Gwanggyo, Korea).
[0132] Experimental procedures that involved animals and their care were conducted in compliance with the Guide for the Care and Use of Laboratory Animals 15 and ARRIVE guidelines. Animal experiments were approved by Animal Care and Use Committee of Woojung center for phenogenomics(Hwasung, Korea) and conducted at WoojungBio Inc.(Hwasung, Korea) in accordance with the guidelines. BALB / C (nu / nu) nude mice of both genders aged 6 weeks and weighing 16-22 g were purchased from Nara biotech Co, Ltd. (Seoul, Korea). The mice were housed in a pathogen-free environment at a temperature of 25°C and relative air humidity between 45 and 50%. All surgeries were performed in a sterile environment. To establish subcutaneous allograft tumors, 1 x 106AsPC-1 cells / 100 pL were subcutaneously injected into the left groin region of BALB / nu nu male mice (7 weeks old; Nara Biotech Inc., Seoul, Korea). Immediately before treatment, IPS-06061 was dissolved in DMSO and then diluted tenfold in normal saline. Tumor-baring mice in vehicle control, IPS-06061 (low), and IPS-06061 (high) groups were injected intravenously with vehicle (1:10 DMSO to saline, v / v), 30 mg / kg IPS-06061 solution, or 80 mg / kg IPS-06061 solution, respectively, twice a week for 28 days (n = 10 mice per major group) (FIG. 11). Tumor growth rate was recorded on day 7, 14, 21, and 28 by measuring the major and minor axes with a digital caliper. Measurements were transformed into tumor volumes using the formula tumor volume (mm3) = major axis x minor axis2x 0.5. Tumor, liver, and kidneys were collected from major groupson day 28 within 3 h of the last injection and weighed. The tumors were subsequently frozen in liquid nitrogen and stored at - 80 °C until homogenization for western blotting.Example 33. Results and Discussion3.1 Results3.1.1. In silico design of a molecular glue using an Orthosteric Approach
[0133] Using the protocol described in section 2.2.1, we have generated a few potential candidate molecules for KRAS G12D mutant, with CRBN as our E3 of choice. Molecular dynamics result reveal that these molecules designed are effective in enhancing the interaction between the POI and E3 ligase, effectively inducing the proximity of the POI to the E3 ligase for successful ubiquitination. Also, the degrading ubiquitination generally occurs at the C- terminal lysine residues of KRAS. The C-terminal is located at the opposite side of the KRAS- CRBN interaction interface, indicating that a degrading ubiquitination is not hindered (FIG. 3 and 4).
[0134] The RMSD (root-mean- square-deviation) of the complex after 10 ns simulations at physiological conditions was analyzed, both with and without the designed molecular glue candidates. When the designed molecule is introduced, the peak RMSD of the ternary complex significantly decreased when compared to that without the MG (FIG. 7). This illustrates the induction of ternary complex stability by the designed molecular glue structure (FIGS. 5 and 6). Using the protocol described above, we generated several potential candidate molecules for the KRAS G12D mutation, and we selected CRBN as E3. Molecular epidemiological results show that these designed molecules are effective in enhancing the interaction between POI and E3 ligase for successful ubiquitination. Moreover, degradation ubiquitination generally occurs at the C-terminal lysine residue in KRAS. The C-terminal is located opposite the KRAS-CRBN interaction interface, indicating that degraded ubiquitination is undisturbed.3.1.2. Ternary complex assay of PPI using a SPR analytical system
[0135] Using the method described in 2.2.6, we carried out ternary complex formation assay using SPR sensor Chip system. We detected sensorgrams of the ternary complex (CRBN- KRAS G12D-IPS06001 complex) when CRBN and KRAS G12D protein were treated with IPS-06001, a new molecular glue(MG) specific for KRAS G12D in a dose-dependent manner (FIG. 8A). However, there was no increased sensorgrams for CRBN-KRAS WT-IPS06001(FIG. 8B). This result suggested that IPS-06001 is a novel MG degrader specific for KRAS G12D, not KRAS WT. See also FIG. 8C.3.1.3. In-vitro Ubiquitination Assay using IPS-Chip PPIExplorer
[0136] To assess whether IPS-06001 enhances ubiquitination of KRAS G12D, Solid Phase Cell-Free Ubiquitination Assay System was developed. Recombinant KRAS G12D protein immobilized on PPIExplorer(IPS-Chip) was increased the ubiquitination of the protein by treatment of IPS-06001 in the presence of CRBN including a reaction mixture containing El, E2 complex, ubiquitin and ATP (FIG. 9). This finding indicated that IPS-06001, a KRAS MGD promoted the ubiquitination of KRAS GI2D in a dose-dependent manner via IPS Chip-based solid-phase cell-free ubiquitination assay.3.1.4. Western blot analysis for KRAS Degradation
[0137] To further examine whether degradation of KRAS G12D in tumor cells is due to ubiquitination of KRAS G12D by IPS-06061 MG, we employed cell-based degradation assay using western blot analysis. IPS-06061 showed time-dependent degradation of KRAS G12D in AsPC-1 pancreatic cancer cells at a DC50 <500 nM and Dmax >90% for KRAS G12D, whereas there was no effect on the degradation of KRAS WT in Caco-2 cells (FIG. 10). These data demonstrated that KRAS GI2D was successfully degraded due to IPS -06061 -induced ubiquitination of the protein.3.1.5. Inhibitory effect of IPS-06061 on the tumor growth in AsPC-1 pancreatic tumor cell-bearing xenograft mice.
[0138] To confirm the anti-tumor effect of IPS-06061, we employed a xenograft mouse model implanting AsPC-1 pancreatic cancer cells. After the tumor volume had grown to approximately 100 mm3, IPS-06061 was administered orally twice a week for 28 days. After the treatments, the mean tumor growth was remarkably reduced in the high dose (80 mpk)- treated group compared to the tumor growth in empty vehicle-treated control group (FIG. 11). Moreover, the treatment of IPS-06061 significantly reduced tumor weight (FIG. 11). Toxicity was assessed by measuring body weight, food intake, complete blood cell count, and biochemical blood chemistry. In the empty vehicle-treated control group, slight decreases in weight and food intake were noted, but such differences were not noted in the IPS-06061- treated group (FIG. 11). Taken together, these data demonstrated that IPS-06061 revealedstrong anti-cancer activity via ubiquitination of KRAS G12D induced by ternary complex formation of CRBN-KRAS G12D-IPS-06061.
[0139] Those skilled in the art will understand that embodiments disclosed herein can be embodied in many different forms and should not be construed as limited to the embodiments set forth in this application. Rather, these embodiments are provided so that this disclosure will fully convey the invention to those skilled in the art. Many modifications and other embodiments of the invention will come to mind in one skilled in the art to which this invention pertains having the benefit of the teachings presented herein.
[0140] All of the various aspects, embodiments, and options described herein can be combined in any and all variations.
[0141] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. To the extent that any meaning or definition of a term in this document conflicts with any meaning or definition of the same term in a document incorporated by reference, the meaning or definition assigned to that term in this document shall govern.
Claims
What is claimed is:
1. A compound of any one of the following structures, enantiomers or diastereomers thereof, or pharmaceutical acceptable salts thereof:
2. A compound of the following structure, an enantiomer or diastereomer thereof, or its pharmaceutical acceptable salt:wherein R is H or Cl to C4 alkyl, and each R’ is independently Cl - C2 alkyl.
3. The compound of claim 2, wherein the compound is, or a pharmaceutical acceptable salt thereof.
4. A compound of the following structure, an enantiomer or diastereomer thereof, or its pharmaceutical acceptable salt:wherein each R is independently Cl to C4 alkyl, and R’ is Cl - C4 alkyl substituted at any position by a phenyl group.
5. The compound of claim 4, wherein the compound is, or a pharmaceutical acceptable salt thereof.
6. A compound of the following structure, an enantiomer or diastereomer thereof, or its pharmaceutical acceptable salt:
7. The compound of claim 6, wherein the compound is, or a pharmaceutical acceptable salt thereof.
8. A pharmaceutical composition comprising at least one of the compounds of any one of claims 1 to 7 or an enantiomer or diastereomer thereof, or its pharmaceutical acceptable salt, and a pharmaceutically acceptable excipient.
9. A method of inhibiting a KRAS G12D and / or G12V mutation in a cell, comprising contacting the cell with the compound of any one of claims 1 to 7 or the pharmaceutical composition of claim 8.
10. A method of treating cancer in a subject in need of treatment, comprising administering to the subject a therapeutically effective amount of the compound of any one of claims 1 to 7 or the pharmaceutical composition of claim 8.
11. The method of claim 10, wherein the cancer is lung cancer, pancreatic cancer, or colorectal cancer.
12. The method of claim 10, wherein the method of treating cancer comprises administering a therapeutic effective amount of an additional pharmaceutically active compound to the subject.
Citation Information
Patent Citations
KRAS G12C mutant protein inhibitor
CN113683616A
KRAS G12D inhibitor and application thereof in medicine
CN115611923A
7-(2-AMINO-1-HYDROXY-ETHYL)-4-HYDROXYBENZOTHIAZOL-2(3H)-ONE-DERIVATIVES AS ß2 ADRENOCEPTOR AGONISTS
WO2007027134A1
KRAS g12c inhibitors
WO2017201161A1
Cited By
Ras inhibitors
WO2025240847A1
Methods of treating a ras protein-related disease or disorder
WO2025255438A1
Therapeutic compositions and methods for managing treatment-related effects
WO2025265060A1
Ras inhibitors
WO2026006747A1
Methods of treating a ras related disease or disorder
WO2026015790A1
